

# Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy

New England Journal of Medicine

366, 1275-1286

DOI: [10.1056/nejmoa1113425](https://doi.org/10.1056/nejmoa1113425)

Citation Report

#	ARTICLE	IF	CITATIONS
3	ADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIVmac251 Challenge. <i>PLoS Pathogens</i> , 2012, 8, e1002890.	2.1	156
4	Natural Immunity to HIV: A Delicate Balance between Strength and Control. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-10.	3.3	21
5	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. <i>Journal of Virology</i> , 2012, 86, 11521-11532.	1.5	357
6	The President's™ Emergency Plan For AIDS Relief: From Successes Of The Emergency Response To Challenges Of Sustainable Action. <i>Health Affairs</i> , 2012, 31, 1380-1388.	2.5	16
7	Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. <i>Aids</i> , 2012, 26, 2155-2163.	1.0	33
8	Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases. <i>Cancer Research</i> , 2012, 72, 3997-4007.	0.4	221
9	Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140. <i>PLoS ONE</i> , 2012, 7, e41144.	1.1	96
10	A DNA-Based Candidate HIV Vaccine Delivered via <i>In Vivo</i> Electroporation Induces CD4 Responses toward the $\pm 4^{27}$ -Binding V2 Loop of HIV gp120 in Healthy Volunteers. <i>Vaccine Journal</i> , 2012, 19, 1557-1559.	3.2	36
11	Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). <i>Journal of Infectious Diseases</i> , 2012, 206, 258-266.	1.9	202
12	Malaria Vaccine Trials "Beyond Efficacy End Points. <i>New England Journal of Medicine</i> , 2012, 367, 2349-2351.	13.9	17
13	Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys. <i>Journal of Virology</i> , 2012, 86, 11434-11440.	1.5	42
14	A mouse model for HIV-1 entry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15859-15864.	3.3	75
15	Accelerated Heterologous Adenovirus Prime-Boost SIV Vaccine in Neonatal Rhesus Monkeys. <i>Journal of Virology</i> , 2012, 86, 7829-7835.	1.5	12
16	Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 987-1000.	1.4	13
17	Poxvirus vectors as HIV/AIDS vaccines in humans. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1192-1207.	1.4	73
18	HIV epidemic in Asia: optimizing and expanding vaccine development. <i>Expert Review of Vaccines</i> , 2012, 11, 805-819.	2.0	10
19	Notable advances 2012. <i>Nature Medicine</i> , 2012, 18, 1732-1734.	15.2	0
20	Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. <i>Nature Medicine</i> , 2012, 18, 1673-1681.	15.2	130

#	ARTICLE	IF	CITATIONS
21	Complex-type <i>N</i> -glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3268-77.	3.3	505
22	Neutralizing Capacity of Monoclonal Antibodies That Recognize Peptide Sequences Underlying the Carbohydrates on gp41 of Simian Immunodeficiency Virus. Journal of Virology, 2012, 86, 12484-12493.	1.5	6
23	Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans. Expert Review of Vaccines, 2012, 11, 539-542.	2.0	5
24	Design by trial. Nature, 2012, 490, 350-351.	13.7	0
25	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses, 2012, 28, 1444-1457.	0.5	191
26	Sequential Evolution and Escape from Neutralization of Simian Immunodeficiency Virus SIVsmE660 Clones in Rhesus Macaques. Journal of Virology, 2012, 86, 8835-8847.	1.5	32
27	Human Vaccines: News. Human Vaccines and Immunotherapeutics, 2012, 8, 1550-1553.	1.4	4
28	The design and evaluation of HIV-1 vaccines. Aids, 2012, 26, 1293-1302.	1.0	41
29	Association of Fcγ3 receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood, 2012, 120, 2836-2842.	0.6	57
30	Deletion of Specific Immune-Modulatory Genes from Modified Vaccinia Virus Ankara-Based HIV Vaccines Engenders Improved Immunogenicity in Rhesus Macaques. Journal of Virology, 2012, 86, 12605-12615.	1.5	34
31	Role of Human Immunodeficiency Virus Type 1 Envelope Structure in the Induction of Broadly Neutralizing Antibodies. Journal of Virology, 2012, 86, 13152-13163.	1.5	23
32	Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infectious Diseases, The, 2012, 12, 531-537.	4.6	201
33	Understanding the efficacy variables of an HIV vaccine trial. Lancet Infectious Diseases, The, 2012, 12, 499-500.	4.6	5
34	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 2012, 433, 410-420.	1.1	12
35	Improved outlook on HIV-1 prevention and vaccine development. Expert Opinion on Biological Therapy, 2012, 12, 983-994.	1.4	5
36	Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. Journal of Virology, 2012, 86, 7760-7770.	1.5	31
38	A Novel Assay for Antibody-Dependent Cell-Mediated Cytotoxicity against HIV-1- or SIV-Infected Cells Reveals Incomplete Overlap with Antibodies Measured by Neutralization and Binding Assays. Journal of Virology, 2012, 86, 12039-12052.	1.5	94
39	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature, 2012, 490, 417-420.	13.7	405

#	ARTICLE	IF	CITATIONS
40	HIV vaccine design: the neutralizing antibody conundrum. <i>Current Opinion in Immunology</i> , 2012, 24, 316-323.	2.4	28
42	HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection. <i>Retrovirology</i> , 2012, 9, 76.	0.9	31
43	Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines. <i>Retrovirology</i> , 2012, 9, 80.	0.9	13
44	The Road to an Effective HIV Vaccine. <i>New England Journal of Medicine</i> , 2012, 366, 1343-1344.	13.9	21
45	Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. <i>Expert Review of Vaccines</i> , 2012, 11, 1459-1470.	2.0	29
46	Human Immunodeficiency Virus Infection : from Biological Observations to Mechanistic Mathematical Modelling. <i>Mathematical Modelling of Natural Phenomena</i> , 2012, 7, 78-104.	0.9	43
47	HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. <i>Trends in Microbiology</i> , 2012, 20, 532-539.	3.5	61
48	Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. <i>Journal of Immunological Methods</i> , 2012, 384, 51-61.	0.6	62
49	HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 767-774.	1.3	7
50	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. <i>Journal of Experimental Medicine</i> , 2012, 209, 1469-1479.	4.2	156
51	The World Must Build On Three Decades Of Scientific Advances To Enable A New Generation To Live Free Of HIV/AIDS. <i>Health Affairs</i> , 2012, 31, 1529-1536.	2.5	14
52	Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of $\hat{1}\pm 4\hat{2}7$ Binding. <i>PLoS ONE</i> , 2012, 7, e39045.	1.1	38
53	A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. <i>PLoS ONE</i> , 2012, 7, e41936.	1.1	74
54	Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2. <i>PLoS ONE</i> , 2012, 7, e42209.	1.1	15
55	MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load. <i>PLoS ONE</i> , 2012, 7, e43396.	1.1	30
56	Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials. <i>PLoS ONE</i> , 2012, 7, e43903.	1.1	30
57	Broad and Cross-Clade CD4+ T-Cell Responses Elicited by a DNA Vaccine Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus Peptides. <i>PLoS ONE</i> , 2012, 7, e45267.	1.1	27
58	Elicitation of Both Anti HIV-1 Env Humoral and Cellular Immunities by Replicating Vaccinia Prime Sendai Virus Boost Regimen and Boosting by CD40Lm. <i>PLoS ONE</i> , 2012, 7, e51633.	1.1	11

#	ARTICLE	IF	CITATIONS
59	An Automated HIV-1 Env-Pseudotyped Virus Production for Global HIV Vaccine Trials. PLoS ONE, 2012, 7, e51715.	1.1	15
60	Vaccine trial reveals chinks in HIV's armour. Nature, 2012, , .	13.7	0
61	HIV antibodies and athletes. Reviews in Medical Virology, 2012, 22, 211-213.	3.9	0
62	Towards an HIV cure: a global scientific strategy. Nature Reviews Immunology, 2012, 12, 607-614.	10.6	485
63	Mining the mechanisms of an HIV vaccine. Nature Medicine, 2012, 18, 1020-1021.	15.2	3
64	Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nature Immunology, 2012, 13, 423-427.	7.0	84
65	Fc-µ fusion proteins: new developments and future perspectives. EMBO Molecular Medicine, 2012, 4, 1015-1028.	3.3	382
66	Universal mapping of humoral immune response using a versatile high-content and high-density peptide microarray. Retrovirology, 2012, 9, .	0.9	0
67	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. Journal of Translational Medicine, 2013, 11, 48.	1.8	3
68	Development of prophylactic vaccines against HIV-1. Retrovirology, 2013, 10, 72.	0.9	64
69	Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology, 2013, 10, 63.	0.9	1
70	Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. Retrovirology, 2013, 10, 33.	0.9	14
71	Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Virology Journal, 2013, 10, 102.	1.4	10
72	Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform. BMC Bioinformatics, 2013, 14, 145.	1.2	10
74	Immunogenic properties of a lettuce-derived C4(V3)6 multiepitopic HIV protein. Planta, 2013, 238, 785-792.	1.6	23
75	Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials. Journal of Immunological Methods, 2013, 394, 84-93.	0.6	43
76	Advances in antiviral vaccine development. Immunological Reviews, 2013, 255, 230-242.	2.8	83
77	HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine, 2013, 31, 3747-3755.	1.7	61

#	ARTICLE	IF	CITATIONS
79	Designing Tomorrow's Vaccines. <i>New England Journal of Medicine</i> , 2013, 368, 551-560.	13.9	237
80	First Steps toward a Globally Effective HIV/AIDS Vaccine. <i>Cell</i> , 2013, 155, 495-497.	13.5	8
81	HIV-AIDS: much accomplished, much to do. <i>Nature Immunology</i> , 2013, 14, 1104-1107.	7.0	38
82	Immune responses to HIV and vaccination. <i>Medicine</i> , 2013, 41, 425-429.	0.2	1
83	Another HIV vaccine failure: where to next?. <i>Nature Medicine</i> , 2013, 19, 1576-1577.	15.2	17
84	Progress towards a hepatitis C virus vaccine. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-7.	3.0	41
85	Antibodies in HIV-1 Vaccine Development and Therapy. <i>Science</i> , 2013, 341, 1199-1204.	6.0	433
86	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	13.9	518
87	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. <i>Cell</i> , 2013, 155, 531-539.	13.5	334
88	Mucosal immunology of HIV infection. <i>Immunological Reviews</i> , 2013, 254, 10-33.	2.8	70
89	HIV-1 neutralizing antibodies: understanding nature's pathways. <i>Immunological Reviews</i> , 2013, 254, 225-244.	2.8	442
90	A global approach to HIV-1 vaccine development. <i>Immunological Reviews</i> , 2013, 254, 295-304.	2.8	57
91	Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. <i>Tuberculosis</i> , 2013, 93, 136-142.	0.8	8
92	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. <i>Retrovirology</i> , 2013, 10, 102.	0.9	39
93	A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. <i>Journal of Immunological Methods</i> , 2013, 395, 1-13.	0.6	19
94	Broadly neutralizing antibodies against HIV-1: Templates for a vaccine. <i>Virology</i> , 2013, 435, 46-56.	1.1	104
95	Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. <i>Immunology</i> , 2013, 138, 116-123.	2.0	139
96	Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 248-256.	1.9	98

#	ARTICLE	IF	CITATIONS
97	First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 240-247.	1.9	144
98	Novel Biopanning Strategy To Identify Epitopes Associated with Vaccine Protection. <i>Journal of Virology</i> , 2013, 87, 4403-4416.	1.5	51
99	Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. <i>Vaccine</i> , 2013, 31, 5789-5797.	1.7	71
100	A neonatal oral <i>Mycobacterium tuberculosis</i> -SIV prime/intramuscular MVA-SIV boost combination vaccine induces both SIV and Mtb-specific immune responses in infant macaques. <i>Trials in Vaccinology</i> , 2013, 2, 53-63.	1.2	19
102	Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling. <i>Virology</i> , 2013, 447, 240-248.	1.1	10
103	Identification of cross-clade CTL epitopes in HIV-1 clade A/E-infected individuals by using the clade B overlapping peptides. <i>Microbes and Infection</i> , 2013, 15, 874-886.	1.0	15
104	Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice. <i>Vaccine</i> , 2013, 31, 5594-5601.	1.7	12
105	HIV-1 vaccine-specific responses induced by <i>Listeria</i> vector vaccines are maintained in mice subsequently infected with a model helminth parasite, <i>Schistosoma mansoni</i> . <i>Vaccine</i> , 2013, 31, 5651-5658.	1.7	3
106	A brief history of the global effort to develop a preventive HIV vaccine. <i>Vaccine</i> , 2013, 31, 3502-3518.	1.7	115
107	Successful vaccination of immune suppressed recipients using <i>Listeria</i> vector HIV-1 vaccines in helminth infected mice. <i>Vaccine</i> , 2013, 31, 2050-2056.	1.7	9
108	Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. <i>Vaccine</i> , 2013, 31, 5506-5517.	1.7	17
109	Innate and adaptive anti-HIV immune responses in the female reproductive tract. <i>Journal of Reproductive Immunology</i> , 2013, 97, 74-84.	0.8	56
110	Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. <i>Vaccine</i> , 2013, 31, B204-B208.	1.7	26
111	Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2013, 87, 4185-4201.	1.5	83
112	Harnessing CD4+ T cell responses in HIV vaccine development. <i>Nature Medicine</i> , 2013, 19, 143-149.	15.2	101
113	Vaccine design: emerging concepts and renewed optimism. <i>Current Opinion in Biotechnology</i> , 2013, 24, 1078-1088.	3.3	32
114	Neutralizing antibodies to HIV-1 induced by immunization. <i>Journal of Experimental Medicine</i> , 2013, 210, 209-223.	4.2	144
115	Broadly Neutralizing Antiviral Antibodies. <i>Annual Review of Immunology</i> , 2013, 31, 705-742.	9.5	447

#	ARTICLE	IF	CITATIONS
116	What mAbs Tell Us about Shapes: Multiple Roads Lead to Rome. <i>Immunity</i> , 2013, 38, 8-9.	6.6	2
117	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	6.6	374
118	Implications of HIV diversity for the HIV-1 pandemic. <i>Journal of Infection</i> , 2013, 66, 391-400.	1.7	122
119	Roadmaps to a vaccine. <i>Nature</i> , 2013, 496, 441-442.	13.7	28
120	Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. <i>Expert Review of Vaccines</i> , 2013, 12, 379-393.	2.0	85
121	Magnetic bacteria on a diamond plate. <i>Nature</i> , 2013, 496, 442-443.	13.7	3
122	Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. <i>Virology</i> , 2013, 439, 81-88.	1.1	20
123	Non-neutralizing antibodies in prevention of HIV infection. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 197-207.	1.4	40
124	Progress in the development of an adenovirus 26 vector platform for HIV vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 477-480.	2.0	3
125	CD8 <sup>+</sup> T cell effector function and transcriptional regulation during HIV pathogenesis. <i>Immunological Reviews</i> , 2013, 254, 190-206.	2.8	60
126	Utilizing poxviral vectored vaccines for antibody induction—Progress and prospects. <i>Vaccine</i> , 2013, 31, 4223-4230.	1.7	44
127	Novel HIV vaccine strategies: overview and perspective. <i>Therapeutic Advances in Vaccines</i> , 2013, 1, 99-112.	2.7	25
128	Beyond RV144 Efficacy Results: An Update. <i>Procedia in Vaccinology</i> , 2013, 7, 49-56.	0.4	8
129	Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. <i>Expert Review of Vaccines</i> , 2013, 12, 365-378.	2.0	31
130	Human immunodeficiency virus vaccines. , 2013, , 1097-1121.		1
131	Animal models in virus research: their utility and limitations. <i>Critical Reviews in Microbiology</i> , 2013, 39, 325-361.	2.7	20
132	Is the current use of “positivity” thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?. <i>Aids</i> , 2013, 27, 1362-1365.	1.0	2
133	Early Infection HIV-1 Envelope V1-V2 Genotypes Do Not Enhance Binding or Replication in Cells Expressing High Levels of $\alpha 4\beta 7$ Integrin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 249-253.	0.9	9



#	ARTICLE	IF	CITATIONS
134	DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. <i>Aids</i> , 2013, 27, 2841-2851.	1.0	21
135	Translation of Biomedical Prevention Strategies for HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S12-S25.	0.9	33
136	Translational Research Insights From Completed HIV Vaccine Efficacy Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S150-S154.	0.9	6
137	An unusual case of HIV virologic failure during treatment with boosted atazanavir. <i>Aids</i> , 2013, 27, 1361-1362.	1.0	8
138	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. <i>Journal of Virology</i> , 2013, 87, 7828-7836.	1.5	59
139	Molecular Evolution of the HIV-1 Thai Epidemic between the Time of RV144 Immunogen Selection to the Execution of the Vaccine Efficacy Trial. <i>Journal of Virology</i> , 2013, 87, 7265-7281.	1.5	26
140	A Novel Rabbit Monoclonal Antibody Platform To Dissect the Diverse Repertoire of Antibody Epitopes for HIV-1 Env Immunogen Design. <i>Journal of Virology</i> , 2013, 87, 10232-10243.	1.5	25
141	The Quest for an HIV-1 Vaccine " Moving Forward. <i>New England Journal of Medicine</i> , 2013, 369, 2073-2076.	13.9	12
142	Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNABs. <i>PLoS Pathogens</i> , 2013, 9, e1003106.	2.1	172
143	Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults. <i>Vaccine Journal</i> , 2013, 20, 397-408.	3.2	23
144	Adoptive Transfer of Lymphocytes Isolated from Simian Immunodeficiency Virus SIVmac239I <sup>nef</sup> -Vaccinated Macaques Does Not Affect Acute-Phase Viral Loads but May Reduce Chronic-Phase Viral Loads in Major Histocompatibility Complex-Matched Recipients. <i>Journal of Virology</i> , 2013, 87, 7382-7392.	1.5	15
145	HIV-1 Vaccine-Induced T-Cell Responses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1. <i>PLoS Pathogens</i> , 2013, 9, e1003404.	2.1	39
146	Reduction of HIV-1 Load in Semen During Follow-up Study of RV144 Vaccine Trial Boosts Interest for Novel Correlates of Immune Protection in Genital Mucosa. <i>Journal of Infectious Diseases</i> , 2013, 207, 1189-1192.	1.9	2
147	A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein. <i>PLoS Computational Biology</i> , 2013, 9, e1003046.	1.5	53
148	Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth. <i>PLoS Pathogens</i> , 2013, 9, e1003173.	2.1	55
149	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV <sub>mac251</sub> Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. <i>Journal of Virology</i> , 2013, 87, 1708-1719.	1.5	130
150	Trivalent Live Attenuated Influenza-Simian Immunodeficiency Virus Vaccines: Efficacy and Evolution of Cytotoxic T Lymphocyte Escape in Macaques. <i>Journal of Virology</i> , 2013, 87, 4146-4160.	1.5	17
151	Progress in HIV-1 vaccine development. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	1.5	45

#	ARTICLE	IF	CITATIONS
152	HIV vaccine research and discovery in the nonhuman primates model. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	1.5	13
153	Nonhuman primate models in AIDS research. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	1.5	118
155	New paradigms for functional HIV-specific nonneutralizing antibodies. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 393-401.	1.5	63
156	Novel directions in HIV-1 vaccines revealed from clinical trials. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 421-431.	1.5	39
157	Sieve analysis in HIV-1 vaccine efficacy trials. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 432-436.	1.5	29
158	Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). <i>Therapeutic Advances in Vaccines</i> , 2013, 1, 67-80.	2.7	7
159	Antibody and Antiretroviral Preexposure Prophylaxis Prevent Cervicovaginal HIV-1 Infection in a Transgenic Mouse Model. <i>Journal of Virology</i> , 2013, 87, 8535-8544.	1.5	24
160	New clinical trial designs for HIV vaccine evaluation. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 437-442.	1.5	6
161	Cautious optimism for HIV vaccine science. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 367-368.	1.5	3
162	Nonreplicating vectors in HIV vaccines. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 412-420.	1.5	37
163	Immune Focusing and Enhanced Neutralization Induced by HIV-1 gp140 Chemical Cross-Linking. <i>Journal of Virology</i> , 2013, 87, 10163-10172.	1.5	43
164	Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk. <i>Journal of Virology</i> , 2013, 87, 6986-6999.	1.5	38
165	Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners. <i>Journal of Virology</i> , 2013, 87, 9053-9063.	1.5	19
166	HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. <i>Mucosal Immunology</i> , 2013, 6, 692-703.	2.7	68
167	Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. <i>Journal of Experimental Medicine</i> , 2013, 210, 2813-2821.	4.2	147
168	Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies. <i>Journal of Virology</i> , 2013, 87, 4882-4894.	1.5	65
169	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. <i>Journal of Virology</i> , 2013, 87, 1554-1568.	1.5	97
170	Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire. <i>Journal of Infectious Diseases</i> , 2013, 207, 1829-1840.	1.9	52

#	ARTICLE	IF	CITATIONS
171	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18214-18219.	3.3	73
172	CCL19 and CCL28 Augment Mucosal and Systemic Immune Responses to HIV-1 gp140 by Mobilizing Responsive Immunocytes into Secondary Lymph Nodes and Mucosal Tissue. Journal of Immunology, 2013, 191, 1935-1947.	0.4	43
173	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9019-9024.	3.3	371
174	Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1231-1239.	1.9	73
176	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2975-2980.	3.3	71
177	Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E69-78.	3.3	138
178	From the Laboratory to Clinical Trials and Back Again: Lessons Learned from HIV Prevention Trials. American Journal of Reproductive Immunology, 2013, 69, 106-115.	1.2	4
179	Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge. Journal of Virology, 2013, 87, 11604-11616.	1.5	44
180	Mucosal Priming with a Replicating-Vaccinia Virus-Based Vaccine Elicits Protective Immunity to Simian Immunodeficiency Virus Challenge in Rhesus Monkeys. Journal of Virology, 2013, 87, 5669-5677.	1.5	55
181	Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120. Journal of Virology, 2013, 87, 10855-10873.	1.5	29
182	Activation of NK cells by HIV-specific ADCC antibodies. Human Vaccines and Immunotherapeutics, 2013, 9, 1011-1018.	1.4	14
183	Toward an effective AIDS vaccine development. European Journal of Immunology, 2013, 43, 3087-3089.	1.6	1
184	Immunology and world health: key contributions from the global community. Annals of the New York Academy of Sciences, 2013, 1283, 1-7.	1.8	2
185	Mark-Specific Hazard Ratio Model with Multivariate Continuous Marks: An Application to Vaccine Efficacy. Biometrics, 2013, 69, 328-337.	0.8	18
186	Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity Antibodies in the Absence of Neutralizing Antibodies. Journal of Immunology, 2013, 190, 1837-1848.	0.4	200
187	Nucleoprotein-specific nonneutralizing antibodies speed up LCMV elimination independently of complement and FcγR. European Journal of Immunology, 2013, 43, 2338-2348.	1.6	34
188	Robust Immunity to an Auxotrophic Mycobacterium bovis BCG-VLP Prime-Boost HIV Vaccine Candidate in a Nonhuman Primate Model. Journal of Virology, 2013, 87, 5151-5160.	1.5	27
189	Cutting Edge: Novel Vaccination Modality Provides Significant Protection against Mucosal Infection by Highly Pathogenic Simian Immunodeficiency Virus. Journal of Immunology, 2013, 190, 2495-2499.	0.4	41

#	ARTICLE	IF	CITATIONS
190	Impact of IgA Constant Domain on HIV-1 Neutralizing Function of Monoclonal Antibody F425A1g8. <i>Journal of Immunology</i> , 2013, 190, 205-210.	0.4	34
191	Complex Correlates of Protection After Vaccination. <i>Clinical Infectious Diseases</i> , 2013, 56, 1458-1465.	2.9	225
193	Roadblocks to translational challenges on viral pathogenesis. <i>Nature Medicine</i> , 2013, 19, 30-34.	15.2	7
194	Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2095-2102.	1.4	12
195	Vaccination with Vaxfectin <sup>®</sup> adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2069-2080.	1.4	12
196	Nonhuman Primate Models for HIV/AIDS Vaccine Development. <i>Current Protocols in Immunology</i> , 2013, 102, 12.14.1-12.14.30.	3.6	45
197	Recent Advances in Humanized Mice: Accelerating the Development of an HIV Vaccine. <i>Journal of Infectious Diseases</i> , 2013, 208, S121-S124.	1.9	15
198	A tale of two vaccines. <i>Aids</i> , 2013, 27, 1-5.	1.0	8
199	Will mosaic vaccine immunogens expand immune response breadth to rival HIV-1 strain diversity?. <i>Clinical Investigation</i> , 2013, 3, 413-415.	0.0	3
200	Anti-HIV IgA isotypes. <i>Aids</i> , 2013, 27, F13-F20.	1.0	114
201	What Has 30 Years of HIV Vaccine Research Taught Us?. <i>Vaccines</i> , 2013, 1, 513-526.	2.1	25
202	Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses. <i>Current HIV Research</i> , 2013, 11, 378-387.	0.2	82
203	Editorial (Thematic Issue: Fc Receptor-Mediated Effector Functions in the Humoral Control of HIV-1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.2	1
204	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e53629.	1.1	165
205	Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. <i>PLoS ONE</i> , 2013, 8, e55438.	1.1	69
206	Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers. <i>PLoS ONE</i> , 2013, 8, e55831.	1.1	41
207	Chimeric HIV-1 Envelope Glycoproteins with Potent Intrinsic Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Activity*. <i>PLoS ONE</i> , 2013, 8, e60126.	1.1	7
208	Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers. <i>PLoS ONE</i> , 2013, 8, e67484.	1.1	8

#	ARTICLE	IF	CITATIONS
209	Genetic Imprint of Vaccination on Simian/Human Immunodeficiency Virus Type 1 Transmitted Viral Genomes in Rhesus Macaques. PLoS ONE, 2013, 8, e70814.	1.1	1
210	Limited Impact of Passive Non-Neutralizing Antibody Immunization in Acute SIV Infection on Viremia Control in Rhesus Macaques. PLoS ONE, 2013, 8, e73453.	1.1	18
211	High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers. PLoS ONE, 2013, 8, e74855.	1.1	76
212	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e75665.	1.1	214
213	Detection of HIV-1 Neutralizing Antibodies in a Human CD4+/CXCR4+/CCR5+ T-Lymphoblastoid Cell Assay System. PLoS ONE, 2013, 8, e77756.	1.1	32
214	A Prime-Pull Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice. PLoS ONE, 2013, 8, e80559.	1.1	19
215	Is Obesity a Risk Factor for Vaccine Non-Responsiveness?. PLoS ONE, 2013, 8, e82779.	1.1	57
216	Envelope Determinants of Equine Lentiviral Vaccine Protection. PLoS ONE, 2013, 8, e66093.	1.1	6
217	Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS ONE, 2013, 8, e66894.	1.1	60
218	Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. Frontiers in Microbiology, 2013, 4, 117.	1.5	8
219	An HIV Vaccine for South-East Asia—Opportunities and Challenges. Vaccines, 2013, 1, 348-366.	2.1	5
220	Trial, Error, and Breakthrough: A Review of HIV Vaccine Development. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	5
221	Optimizing Viable Leukocyte Sampling from the Female Genital Tract for Clinical Trials: An International Multi-Site Study. PLoS ONE, 2014, 9, e85675.	1.1	73
222	Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies. PLoS ONE, 2014, 9, e86905.	1.1	22
223	Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011). PLoS ONE, 2014, 9, e91366.	1.1	23
224	DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques. PLoS ONE, 2014, 9, e91550.	1.1	42
225	Regulation of SIV Antigen-Specific CD4+ T Cellular Immunity via Autophagosome-Mediated MHC II Molecule-Targeting Antigen Presentation in Mice. PLoS ONE, 2014, 9, e93143.	1.1	44
226	Estimated Secondary Structure Propensities within V1/V2 Region of HIV gp120 Are an Important Global Antibody Neutralization Sensitivity Determinant. PLoS ONE, 2014, 9, e94002.	1.1	13

#	ARTICLE	IF	CITATIONS
227	Immunization of Rabbits with Highly Purified, Soluble, Trimeric Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Induces a Vigorous B Cell Response and Broadly Cross-Reactive Neutralization. PLoS ONE, 2014, 9, e98060.	1.1	5
228	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. PLoS ONE, 2014, 9, e101863.	1.1	36
229	Cryptic Determinant of $\hat{I}\pm 4\hat{I}^27$ Binding in the V2 Loop of HIV-1 gp120. PLoS ONE, 2014, 9, e108446.	1.1	33
230	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon- $\hat{I}^3$ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study. PLoS ONE, 2014, 9, e108631.	1.1	23
231	A Mammalian Cell Based FACS-Panning Platform for the Selection of HIV-1 Envelopes for Vaccine Development. PLoS ONE, 2014, 9, e109196.	1.1	6
232	An HIV-1 Envelope Immunogen with W427S Mutation in CD4 Binding Site Induced More T Follicular Helper Memory Cells and Reduced Non-Specific Antibody Responses. PLoS ONE, 2014, 9, e115047.	1.1	4
234	Design Challenges for HIV-1 Vaccines Based on Humoral Immunity. Frontiers in Immunology, 2014, 5, 335.	2.2	10
235	Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Advances in Biology, 2014, 2014, 1-24.	1.2	194
236	Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. Vaccines, 2014, 2, 15-35.	2.1	41
237	HIV/AIDS Prevention. , 2014, , 100-111.e2.		3
238	The Pursuit of a HIV Vaccine â€“ Trials, Challenges and Strategies. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	1
239	The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. Expert Review of Vaccines, 2014, 13, 1489-1500.	2.0	28
240	Progress in HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2014, 134, 3-10.	1.5	62
241	Enhancing poxvirus vectors vaccine immunogenicity. Human Vaccines and Immunotherapeutics, 2014, 10, 2235-2244.	1.4	73
242	Comparison of Antibodies That Mediate HIV Type 1 gp120 Antibody-Dependent Cell-Mediated Cytotoxicity in Asymptomatic HIV Type 1-Positive Men and Women. AIDS Research and Human Retroviruses, 2014, 30, 50-57.	0.5	4
243	Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12. Virologica Sinica, 2014, 29, 299-307.	1.2	5
244	Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology, 2014, 11, 78.	0.9	26
245	Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domainâ€™s exceptional capacity for sequence variation. Retrovirology, 2014, 11, 75.	0.9	16

#	ARTICLE	IF	CITATIONS
246	HIV-1 Envelope Proteins and V1/V2 Domain Scaffolds with Mannose-5 to Improve the Magnitude and Quality of Protective Antibody Responses to HIV-1. <i>Journal of Biological Chemistry</i> , 2014, 289, 20526-20542.	1.6	24
247	Divergent Antibody Subclass and Specificity Profiles but Not Protective HLA-B Alleles Are Associated with Variable Antibody Effector Function among HIV-1 Controllers. <i>Journal of Virology</i> , 2014, 88, 2799-2809.	1.5	46
248	Broad and Potent Cellular and Humoral Immune Responses After a Second Late HIV-Modified Vaccinia Virus Ankara Vaccination in HIV-DNA-Primed and HIV-Modified Vaccinia Virus Ankara-Boosted Swedish Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 299-311.	0.5	31
249	Systems vaccinology: Probing humanity's diverse immune systems with vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 12300-12306.	3.3	162
250	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. <i>Molecular Therapy</i> , 2014, 22, 464-475.	3.7	188
252	Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 601-616.	1.4	57
253	Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A. <i>Vaccine Journal</i> , 2014, 21, 1005-1011.	3.2	15
254	Which Antibody Functions are Important for an HIV Vaccine?. <i>Frontiers in Immunology</i> , 2014, 5, 289.	2.2	47
255	Mother's Infant HIV Transmission: Do Maternal HIV-Specific Antibodies Protect the Infant?. <i>PLoS Pathogens</i> , 2014, 10, e1004283.	2.1	16
256	Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. <i>Clinical Immunology</i> , 2014, 155, 91-107.	1.4	24
257	The FcγR of Humans and Non-human Primates and Their Interaction with IgG: Implications for Induction of Inflammation, Resistance to Infection and the Use of Therapeutic Monoclonal Antibodies. <i>Current Topics in Microbiology and Immunology</i> , 2014, 382, 321-352.	0.7	24
258	The Rise and Fall of HIV in High-Prevalence Countries: A Challenge for Mathematical Modeling. <i>PLoS Computational Biology</i> , 2014, 10, e1003459.	1.5	22
259	Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1. <i>PLoS Pathogens</i> , 2014, 10, e1004552.	2.1	34
260	Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. <i>Frontiers in Immunology</i> , 2014, 5, 202.	2.2	14
261	Immunity to HIV in Early Life. <i>Frontiers in Immunology</i> , 2014, 5, 391.	2.2	70
262	Biomarkers of Safety and Immune Protection for Genetically Modified Live Attenuated Leishmania Vaccines Against Visceral Leishmaniasis: Discovery and Implications. <i>Frontiers in Immunology</i> , 2014, 5, 241.	2.2	45
263	Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models. <i>Viruses</i> , 2014, 6, 3129-3158.	1.5	10
264	Characterization of T-Cell Responses to Cryptic Epitopes in Recipients of a Noncodon-Optimized HIV-1 Vaccine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 142-150.	0.9	4

#	ARTICLE	IF	CITATIONS
265	Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1-Infected Women in Uganda (HPTN 027). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 268-277.	0.9	13
266	Innate Immunity in Simian Immunodeficiency Virus Infection. , 2014, , 135-172.		0
267	HIV Prevention and Treatment Fields Join Forces. <i>EBioMedicine</i> , 2014, 1, 4-5.	2.7	2
268	The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens. <i>Expert Review of Vaccines</i> , 2014, 13, 935-937.	2.0	1
269	Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2507-2511.	1.4	6
270	Anti-HIV Antibody-Dependent Activation of NK Cells Impairs NKp46 Expression. <i>Journal of Immunology</i> , 2014, 192, 308-315.	0.4	39
271	Dissecting the antibody constant region protective immune parameters in HIV infection. <i>Future Virology</i> , 2014, 9, 397-414.	0.9	8
272	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. <i>Journal of Immunology</i> , 2014, 193, 6172-6183.	0.4	34
273	Could vaccination with AIDS VAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3013-3016.	1.4	9
274	Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2679-2683.	1.4	14
275	Temporal-lobe morphology differs between healthy adolescents and those with early-onset of depression. <i>NeuroImage: Clinical</i> , 2014, 6, 145-155.	1.4	35
276	Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus. <i>Vaccine</i> , 2014, 32, 6527-6536.	1.7	9
277	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. <i>EBioMedicine</i> , 2014, 1, 37-45.	2.7	55
278	The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys. <i>Journal of Virology</i> , 2014, 88, 1809-1814.	1.5	62
279	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	1.5	169
280	Strategies for Preventing Mucosal Cell-Associated HIV Transmission. <i>Journal of Infectious Diseases</i> , 2014, 210, S674-S680.	1.9	12
281	Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2014, 210, 99-110.	1.9	73
282	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	6.6	65



#	ARTICLE	IF	CITATIONS
283	Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. <i>EMBO Molecular Medicine</i> , 2014, 6, 1436-1454.	3.3	45
284	Review article: the intersection of mucosal pathophysiology in HIV and inflammatory bowel disease, and its implications for therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1171-1186.	1.9	12
285	Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. <i>European Journal of Immunology</i> , 2014, 44, 2802-2810.	1.6	102
286	Accelerating HIV-1 Vaccine Efficacy Trials. <i>Cell</i> , 2014, 159, 969-972.	13.5	17
287	HIV-1 Envelope Glycoprotein Trimer Immunogenicity Elicited in the Presence of Human CD4 Alters the Neutralization Profile. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1089-1098.	0.5	6
288	Comment on Clinical Development of Candidate HIV Vaccines: Different Problems for Different Vaccines. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 331-332.	0.5	0
289	Sequence-Conserved and Antibody-Accessible Sites in the V1V2 Domain of HIV-1 gp120 Envelope Protein. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 927-931.	0.5	2
290	Role of Fc-mediated antibody function in protective immunity against HIV-1. <i>Immunology</i> , 2014, 142, 46-57.	2.0	69
291	Envelope Glycoprotein Binding to the Integrin $\alpha 4 \beta 7$ Is Not a General Property of Most HIV-1 Strains. <i>Journal of Virology</i> , 2014, 88, 10767-10777.	1.5	25
292	Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6425-6430.	3.3	143
293	Enhanced Fusion and Virion Incorporation for HIV-1 Subtype C Envelope Glycoproteins with Compact V1/V2 Domains. <i>Journal of Virology</i> , 2014, 88, 2083-2094.	1.5	17
294	Association between Cellular Immune Activation, Target Cell Frequency, and Risk of Human Immunodeficiency Virus Type 1 Superinfection. <i>Journal of Virology</i> , 2014, 88, 5894-5899.	1.5	5
295	Targeting Cellular Cofactors in HIV Therapy. <i>Topics in Medicinal Chemistry</i> , 2014, , 183-222.	0.4	8
296	HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage. <i>Retrovirology</i> , 2014, 11, 99.	0.9	9
297	Are anti-HIV IgAs good guys or bad guys?. <i>Retrovirology</i> , 2014, 11, 109.	0.9	28
298	Spectrum of HIV antibodies in vaccine and disease. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 207-209.	1.5	1
299	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	5.8	412
300	Recent progress in HIV vaccines inducing mucosal immune responses. <i>Aids</i> , 2014, 28, 1701-1718.	1.0	19

#	ARTICLE	IF	CITATIONS
301	T follicular helper cells and HIV/SIV-specific antibody responses. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 235-241.	1.5	22
302	Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag. <i>Aids</i> , 2014, 28, 2786-2788.	1.0	5
303	Adeno-associated virus delivery of broadly neutralizing antibodies. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 250-256.	1.5	27
304	Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. <i>Science Translational Medicine</i> , 2014, 6, 228ra38.	5.8	367
305	Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. <i>Aids</i> , 2014, 28, 2523-2530.	1.0	108
306	Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation. <i>Aids</i> , 2014, 28, 2781-2786.	1.0	20
307	Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines. <i>Aids</i> , 2014, 28, 2495-2504.	1.0	10
308	Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 263-270.	1.5	30
309	Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants. <i>Vaccine Journal</i> , 2014, 21, 391-398.	3.2	13
310	HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1734-1746.	1.4	30
311	Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics. <i>Biostatistics</i> , 2014, 15, 196-203.	0.9	13
312	Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens. <i>Journal of Virology</i> , 2014, 88, 3392-3410.	1.5	41
313	Physicochemical and functional characterization of vaccine antigens and adjuvants. <i>Expert Review of Vaccines</i> , 2014, 13, 671-685.	2.0	40
314	Human Immunodeficiency Viruses Types 1 and 2. , 2014, , 1001-1062.		0
315	Identifying Opportunities to Block HIV-1 Transmission in the Female Genital Tract. , 2014, , 1-10.		0
316	SIVmac Infection of Macaques, Immunopathogenesis of. , 2014, , 1-15.		1
317	Role of Antibodies in HIV Transmission. , 2014, , 1-9.		0
318	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. <i>Vaccine Journal</i> , 2014, 21, 1589-1599.	3.2	10

#	ARTICLE	IF	CITATIONS
319	Cure of HIV infection: Is the long wait over?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 20-22.	1.5	0
320	A Paradigm Shift: Vaccine-Induced Antibodies as an Immune Correlate of Protection Against Herpes Simplex Virus Type 1 Genital Herpes. <i>Journal of Infectious Diseases</i> , 2014, 209, 813-815.	1.9	13
321	Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu056.	0.4	19
322	More Surprises in the Development of an HIV Vaccine. <i>Frontiers in Immunology</i> , 2014, 5, 329.	2.2	3
323	The Significance of Interferon- $\beta$ in HIV-1 Pathogenesis, Therapy, and Prophylaxis. <i>Frontiers in Immunology</i> , 2014, 4, 498.	2.2	94
324	The role of Fc receptors in HIV infection and vaccine efficacy. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 257-262.	1.5	19
325	Immunogen design to focus the B-cell repertoire. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 217-223.	1.5	13
326	Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity. <i>Aids</i> , 2014, 28, 1859-1870.	1.0	37
327	Resistance to Infection, Early and Persistent Suppression of Simian Immunodeficiency Virus SIV $\beta$ Viremia, and Significant Reduction of Tissue Viral Burden after Mucosal Vaccination in Female Rhesus Macaques. <i>Journal of Virology</i> , 2014, 88, 212-224.	1.5	19
328	Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV. <i>Journal of Virology</i> , 2014, 88, 4100-4112.	1.5	40
329	Host factors determine differential disease progression after infection with nef-deleted simian immunodeficiency virus. <i>Journal of General Virology</i> , 2014, 95, 2273-2284.	1.3	2
330	Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. <i>Journal of Immunological Methods</i> , 2014, 409, 107-116.	0.6	34
332	Improvement of antibody responses by HIV envelope DNA and protein co-immunization. <i>Vaccine</i> , 2014, 32, 507-513.	1.7	35
333	Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. <i>Journal of Virology</i> , 2014, 88, 2633-2644.	1.5	237
334	Emerging concepts on T follicular helper cell dynamics in HIV infection. <i>Trends in Immunology</i> , 2014, 35, 278-286.	2.9	35
335	HIV-1 Vpu Antagonism of Tetherin Inhibits Antibody-Dependent Cellular Cytotoxic Responses by Natural Killer Cells. <i>Journal of Virology</i> , 2014, 88, 6031-6046.	1.5	118
336	Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. <i>Retrovirology</i> , 2014, 11, 8.	0.9	12
337	The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?!. <i>Virologica Sinica</i> , 2014, 29, 7-9.	1.2	6

#	ARTICLE	IF	CITATIONS
338	Human immunodeficiency virus antibodies and the vaccine problem. <i>Journal of Internal Medicine</i> , 2014, 275, 444-455.	2.7	6
339	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	13.7	681
340	Distinct advancements and challenges in HIV 1 vaccine development and cure—A review. <i>HIV and AIDS Review</i> , 2014, 13, 1-5.	0.1	3
341	Challenges and responses in human vaccine development. <i>Current Opinion in Immunology</i> , 2014, 28, 18-26.	2.4	60
342	Vaccines that stimulate T cell immunity to HIV-1: the next step. <i>Nature Immunology</i> , 2014, 15, 319-322.	7.0	72
343	Antibody-Dependent Cellular Cytotoxicity (ADCC). , 2014, , 1-27.		22
344	Humoral Immune Responses to <sc>HIV</sc> in the Mucosal Secretions and Sera of <sc>HIV</sc>-Infected Women. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 600-607.	1.2	11
345	Novel approaches in polyepitope T-cell vaccine development against HIV-1. <i>Expert Review of Vaccines</i> , 2014, 13, 155-173.	2.0	25
346	First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). <i>Journal of Infectious Diseases</i> , 2014, 210, 1052-1061.	1.9	25
347	Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies. <i>Nature Medicine</i> , 2014, 20, 478-479.	15.2	9
348	HIV Vaccines: A Brief Overview. <i>Scandinavian Journal of Immunology</i> , 2014, 80, 1-11.	1.3	26
349	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	13.7	140
350	Short Communication: Anti-HIV-1 Envelope Immunoglobulin Gs in Blood and Cervicovaginal Samples of Beninese Commercial Sex Workers. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1145-1149.	0.5	24
351	Induction of Intestinal Immunity by Mucosal Vaccines As a Means of Controlling HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1027-1040.	0.5	16
352	Problems in Vaccine Development. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2014, 33, 166-167.	0.8	3
353	The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques. <i>Journal of General Virology</i> , 2014, 95, 2267-2272.	1.3	16
354	Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15614-15621.	3.3	88
355	HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. <i>Virology</i> , 2014, 471-473, 81-92.	1.1	21

#	ARTICLE	IF	CITATIONS
356	Advancing HIV prevention science: the roads from Cape Town. <i>Lancet</i> , The, 2014, 384, 1725-1727.	6.3	0
357	The Immune Space: A Concept and Template for Rationalizing Vaccine Development. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1017-1022.	0.5	11
358	Common Features of Mucosal and Peripheral Antibody Responses Elicited by Candidate HIV-1 Vaccines in Rhesus Monkeys. <i>Journal of Virology</i> , 2014, 88, 13510-13515.	1.5	5
359	Commentary: HIV Vaccine Trial Exploits a Dual and Central Role for Innate Immunity. <i>Journal of Virology</i> , 2014, 88, 11640-11643.	1.5	3
360	Envelope Variants Circulating as Initial Neutralization Breadth Developed in Two HIV-Infected Subjects Stimulate Multiclude Neutralizing Antibodies in Rabbits. <i>Journal of Virology</i> , 2014, 88, 12949-12967.	1.5	37
361	Diverse Recombinant HIV-1 Envs Fail To Activate B Cells Expressing the Germline B Cell Receptors of the Broadly Neutralizing Anti-HIV-1 Antibodies PG9 and 447-52D. <i>Journal of Virology</i> , 2014, 88, 2645-2657.	1.5	69
362	Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. <i>Journal of Virological Methods</i> , 2014, 208, 107-114.	1.0	62
363	Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2014, 88, 3329-3339.	1.5	80
364	Distinct Mechanisms Regulate Exposure of Neutralizing Epitopes in the V2 and V3 Loops of HIV-1 Envelope. <i>Journal of Virology</i> , 2014, 88, 12853-12865.	1.5	53
365	Human Immunodeficiency Virus Vaccines. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 615-631.	1.9	5
366	Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. <i>Virus Research</i> , 2014, 192, 25-33.	1.1	6
367	Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120. <i>Molecular Immunology</i> , 2014, 62, 219-226.	1.0	5
368	Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection. <i>Virology</i> , 2014, 462-463, 295-298.	1.1	6
369	HIV-specific antibody-dependent phagocytosis matures during HIV infection. <i>Immunology and Cell Biology</i> , 2014, 92, 679-687.	1.0	29
370	TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: "How can big data help?". <i>Vaccine</i> , 2014, 32, 4365-4368.	1.7	4
371	Sida: conceptos inmunológicos y clínicos básicos. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2014, 21, 325-335.	0.0	0
372	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducibile Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. <i>Journal of Virology</i> , 2014, 88, 9406-9417.	1.5	16
373	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. <i>Journal of Virology</i> , 2014, 88, 8242-8255.	1.5	55

#	ARTICLE	IF	CITATIONS
374	CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies. <i>Journal of Virology</i> , 2014, 88, 6542-6555.	1.5	55
375	Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2014, 88, 12968-12981.	1.5	51
376	Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. <i>Vaccine</i> , 2014, 32, 4916-4924.	1.7	9
377	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. <i>Journal of Virology</i> , 2014, 88, 12623-12643.	1.5	75
378	Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection. <i>Journal of Virology</i> , 2014, 88, 12895-12906.	1.5	108
379	Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection. <i>AIDS Research and Therapy</i> , 2014, 11, 23.	0.7	29
380	Antibody B cell responses in HIV-1 infection. <i>Trends in Immunology</i> , 2014, 35, 549-561.	2.9	91
381	HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. <i>Immunogenetics</i> , 2014, 66, 299-310.	1.2	14
382	Highly Efficient Neutralization by Plasma Antibodies from Human Immunodeficiency Virus Type-1 Infected Individuals on Antiretroviral Drug Therapy. <i>Journal of Clinical Immunology</i> , 2014, 34, 504-513.	2.0	4
383	A critical question for HIV vaccine development: Which antibodies to induce?. <i>Science</i> , 2014, 345, 167-168.	6.0	29
384	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. <i>Retrovirology</i> , 2014, 11, 32.	0.9	9
385	Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors. <i>Journal of Experimental Medicine</i> , 2014, 211, 1273-1280.	4.2	76
386	Use of Principal Components Analysis and Protein Microarray to Explore the Association of HIV-1-Specific IgG Responses with Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 37-44.	0.5	4
387	Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza Vaccine. <i>Journal of Immunology</i> , 2014, 193, 469-475.	0.4	112
388	Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy. <i>Vaccine</i> , 2014, 32, 5703-5714.	1.7	22
390	Identification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques. <i>Virology</i> , 2014, 458-459, 53-68.	1.1	15
391	Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. <i>Journal of Immunological Methods</i> , 2014, 404, 1-12.	0.6	35
392	Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein. <i>Journal of Immunology</i> , 2014, 192, 5802-5812.	0.4	4

#	ARTICLE	IF	CITATIONS
393	Vaccines for the 21st century. <i>EMBO Molecular Medicine</i> , 2014, 6, 708-720.	3.3	342
394	Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens. <i>International Immunology</i> , 2014, 26, 531-538.	1.8	61
395	Stabilizing the Native Trimer of HIV-1 Env by Destabilizing the Heterodimeric Interface of the gp41 Postfusion Six-Helix Bundle. <i>Journal of Virology</i> , 2014, 88, 9590-9604.	1.5	42
396	Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. <i>Immunology and Cell Biology</i> , 2014, 92, 359-367.	1.0	29
397	Nonneutralizing Functional Antibodies: a New "Old" Paradigm for HIV Vaccines. <i>Vaccine Journal</i> , 2014, 21, 1023-1036.	3.2	107
398	HIV infection: epidemiology, pathogenesis, treatment, and prevention. <i>Lancet, The</i> , 2014, 384, 258-271.	6.3	616
399	Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. <i>Clinical Immunology</i> , 2014, 153, 308-322.	1.4	20
400	Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials. <i>Journal of Immunological Methods</i> , 2014, 411, 23-36.	0.6	23
401	Loss of a Conserved N-Linked Glycosylation Site in the Simian Immunodeficiency Virus Envelope Glycoprotein V2 Region Enhances Macrophage Tropism by Increasing CD4-Independent Cell-to-Cell Transmission. <i>Journal of Virology</i> , 2014, 88, 5014-5028.	1.5	24
402	Immunogen design for HIV-1 and influenza. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 1891-1906.	1.1	23
403	Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. <i>Mucosal Immunology</i> , 2014, 7, 46-56.	2.7	152
404	Vector-Mediated In Vivo Antibody Expression. <i>Microbiology Spectrum</i> , 2014, 2, AID-0016-2014.	1.2	10
405	HIV DNA Vaccine: Stepwise Improvements Make a Difference. <i>Vaccines</i> , 2014, 2, 354-379.	2.1	37
406	Paradox of Protection: Preferential Recognition of CD4-induced Epitopes by Anti-HIV-1 ADCC Antibodies. <i>EBioMedicine</i> , 2015, 2, 1298-1299.	2.7	0
407	Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques. <i>Immunity, Inflammation and Disease</i> , 2015, 3, 82-93.	1.3	8
408	Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs. <i>Scientific Reports</i> , 2015, 5, 11856.	1.6	21
409	Antibodies Targeting the Envelope of HIV-1. <i>Microbiology Spectrum</i> , 2015, 3, AID-0025-2014.	1.2	9
410	HIV infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15035.	18.1	340

#	ARTICLE	IF	CITATIONS
411	Effects of neutralizing antibodies on escape from CD8 + T-cell responses in HIV-1 infection. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140290.	1.8	6
412	Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study. <i>Journal of Virology</i> , 2015, 89, 12388-12400.	1.5	12
413	Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10780-10785.	3.3	36
414	Antibodies for prevention of mother-to-child transmission of HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 177-182.	1.5	8
415	Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C <sc>HIV</sc>â€1 isolate in rhesus macaques. <i>Journal of Medical Primatology</i> , 2015, 44, 275-285.	0.3	4
416	The role of Fc receptors in <sc>HIV</sc> prevention and therapy. <i>Immunological Reviews</i> , 2015, 268, 296-310.	2.8	41
417	Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity. <i>Aids</i> , 2015, 29, 1433-1443.	1.0	12
418	Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 160-169.	1.5	21
419	Change point testing in logistic regression models with interaction term. <i>Statistics in Medicine</i> , 2015, 34, 1483-1494.	0.8	20
420	Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 1-8.	0.9	10
421	Prime-Boost Vaccination: Impact on the HIV-1 Vaccine Field. , 2015, , 289-313.		1
422	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. <i>Journal of AIDS &amp; Clinical Research</i> , 2015, 06, .	0.5	17
423	Topical Mucosal Vaccination with Angiotensin (1-7) and Feline Immunodeficiency Virus Induces Secretory IgA Responses. , 2015, 04, .		0
424	Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. <i>Viruses</i> , 2015, 7, 5115-5132.	1.5	42
425	Protein Crystallography in Vaccine Research and Development. <i>International Journal of Molecular Sciences</i> , 2015, 16, 13106-13140.	1.8	54
426	Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters. <i>Journal of AIDS &amp; Clinical Research</i> , 2015, 06, .	0.5	1
427	Evaluation of Candidate Biomarkers of Type 1 Diabetes via the Core for Assay Validation. <i>Biomarker Insights</i> , 2015, 10s4, BMI.S29697.	1.0	11
428	Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines. , 2015, , 251-287.		2



#	ARTICLE	IF	CITATIONS
429	Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?. <i>Frontiers in Immunology</i> , 2015, 6, 265.	2.2	24
430	HIV-1 Cell-to-Cell Transmission and Antiviral Strategies: An Overview. <i>Current Drug Targets</i> , 2015, 17, 65-75.	1.0	8
431	Comparison of the Specificities of IgG, IgG-Subclass, IgA and IgM Reactivities in African and European HIV-Infected Individuals with an HIV-1 Clade C Proteome-Based Array. <i>PLoS ONE</i> , 2015, 10, e0117204.	1.1	14
432	Heterologous Prime-Boost Regimens with a Recombinant Chimpanzee Adenoviral Vector and Adjuvanted F4 Protein Elicit Polyfunctional HIV-1-Specific T-Cell Responses in Macaques. <i>PLoS ONE</i> , 2015, 10, e0122835.	1.1	10
433	Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. <i>PLoS ONE</i> , 2015, 10, e0127998.	1.1	2
434	Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies. <i>PLoS ONE</i> , 2015, 10, e0141233.	1.1	10
435	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	2.1	145
436	HIV Vaccine Research: The Challenge and the Way Forward. <i>Journal of Immunology Research</i> , 2015, 2015, 1-5.	0.9	33
437	Receptor Binding Domain Based HIV Vaccines. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	5
438	Low incidence of HIV infection in an anonymous HIV counselling and testing clinic cohort in Bangkok, Thailand despite high HIV prevalence and self-report of high-risk behaviour. <i>Journal of Virus Eradication</i> , 2015, 1, 78-88.	0.3	0
439	Adenovirus vectors as HIV-1 vaccines. <i>Aids</i> , 2015, 29, 395-400.	1.0	9
440	Therapy of Viral Infections. <i>Topics in Medicinal Chemistry</i> , 2015, , .	0.4	6
441	A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. <i>Molecular Immunology</i> , 2015, 66, 364-374.	1.0	30
442	Fc $\gamma$ 3R dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. <i>Trends in Immunology</i> , 2015, 36, 325-336.	2.9	157
443	Infant HIV-1 Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1513.	3.8	7
444	Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. <i>Nature Reviews Microbiology</i> , 2015, 13, 414-425.	13.6	179
445	HIV microarray for the mapping and characterization of HIV-specific antibody responses. <i>Lab on A Chip</i> , 2015, 15, 1574-1589.	3.1	17
446	New approaches to HIV vaccine development. <i>Current Opinion in Immunology</i> , 2015, 35, 39-47.	2.4	77

#	ARTICLE	IF	CITATIONS
447	Natural killer cell heterogeneity: cellular dysfunction and significance in HIV-1 immuno-pathogenesis. Cellular and Molecular Life Sciences, 2015, 72, 3037-3049.	2.4	16
448	Mucosal Immunity and Vaccines Against Simian Immunodeficiency Virus and Human Immunodeficiency Virus. , 2015, , 1171-1182.		1
449	Filling the Immunological Gap. , 2015, , 1291-1306.		3
450	Simian Immunodeficiency Virus Infection and Mucosal Immunity. , 2015, , 1493-1520.		2
451	HIV-1 vaccine immunogen design strategies. Virology Journal, 2015, 12, 3.	1.4	42
452	COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnology, 2015, 33, 610-616.	9.4	232
453	Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. Journal of Virology, 2015, 89, 7813-7828.	1.5	35
454	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	1.5	40
455	Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope. Journal of Virology, 2015, 89, 8130-8151.	1.5	35
456	Gene Transfer for Prophylaxis and Therapy of Viral Infections. , 2015, , 317-354.		0
457	HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and are Commonly Detected in Plasma from HIV-infected Humans. EBioMedicine, 2015, 2, 1464-1477.	2.7	60
458	Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. EBioMedicine, 2015, 2, 2062-2069.	2.7	14
459	HIV-Specific Antibody Responses in HIV-Infected Patients: From a Monoclonal to a Polyclonal View. International Archives of Allergy and Immunology, 2015, 167, 223-241.	0.9	8
460	Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIV. Annales Pharmaceutiques Francaises, 2015, 73, 169-179.	0.4	6
461	Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. Journal of Infectious Diseases, 2015, 211, 1943-1952.	1.9	15
462	Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology, 2015, 475, 187-203.	1.1	22
463	Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. Journal of Immunological Methods, 2015, 416, 105-123.	0.6	37
464	HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians. Vaccine, 2015, 33, 1243-1249.	1.7	32

#	ARTICLE	IF	CITATIONS
465	Virological features associated with the development of broadly neutralizing antibodies to HIV-1. <i>Trends in Microbiology</i> , 2015, 23, 204-211.	3.5	77
466	Pathophysiology of T follicular helper cells in humans and mice. <i>Nature Immunology</i> , 2015, 16, 142-152.	7.0	371
467	Kernel-based logistic regression model for protein sequence without vectorialization. <i>Biostatistics</i> , 2015, 16, 480-492.	0.9	3
468	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E992-9.	3.3	117
469	Trying to cure HIV with immunotherapy: not so simple. <i>Lancet HIV</i> , 2015, 2, e72-e73.	2.1	0
470	Recent developments in clinical trial designs for HIV vaccine research. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1022-1029.	1.4	7
471	Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice. <i>Molecular Therapy</i> , 2015, 23, 1663-1670.	3.7	5
472	A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine. <i>Frontiers in Immunology</i> , 2015, 6, 124.	2.2	26
474	Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. <i>Journal of Virology</i> , 2015, 89, 8840-8854.	1.5	51
475	Toward an HIV vaccine: A scientific journey. <i>Science</i> , 2015, 349, 386-387.	6.0	22
476	Prospects for a globally effective HIV-1 vaccine. <i>Vaccine</i> , 2015, 33, D4-D12.	1.7	28
477	Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1489-1493.	1.4	4
478	An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 9154-9166.	1.5	14
479	Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8379-8384.	3.3	14
480	The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel. <i>Journal of Virology</i> , 2015, 89, 8003-8010.	1.5	68
481	Antigenic Properties of the Human Immunodeficiency Virus Envelope Glycoprotein Gp120 on Virions Bound to Target Cells. <i>PLoS Pathogens</i> , 2015, 11, e1004772.	2.1	43
482	Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. <i>Journal of Virology</i> , 2015, 89, 7478-7493.	1.5	33
483	Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1160-1165.	0.5	14

#	ARTICLE	IF	CITATIONS
484	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>PLoS Computational Biology</i> , 2015, 11, e1003973.	1.5	51
485	Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses. <i>Journal of Infectious Diseases</i> , 2015, 211, 508-517.	1.9	57
486	Transient global T cell activation after vaccination of rhesus macaques with a DNA-poxvirus vaccine regimen for HIV. <i>Vaccine</i> , 2015, 33, 3435-3439.	1.7	1
487	Trials and tribulations on the path to developing a dengue vaccine. <i>Vaccine</i> , 2015, 33, D24-D31.	1.7	30
488	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	5.8	47
489	What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. <i>Journal of Virology</i> , 2015, 89, 5981-5995.	1.5	25
490	Reevaluating HIV Vaccine Clinical Trials Policy for Infants. <i>Journal of Infectious Diseases</i> , 2015, 211, 501-503.	1.9	3
491	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	6.0	303
492	Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees. <i>PLoS Computational Biology</i> , 2015, 11, e1004185.	1.5	50
493	Increasing Complexity of Vaccine Development. <i>Journal of Infectious Diseases</i> , 2015, 212, S12-S16.	1.9	20
494	Well-Ordered Trimeric HIV-1 Subtype B and C Soluble Spike Mimetics Generated by Negative Selection Display Native-like Properties. <i>PLoS Pathogens</i> , 2015, 11, e1004570.	2.1	106
496	Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge. <i>Vaccine</i> , 2015, 33, 2086-2095.	1.7	63
497	HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. <i>Vaccine</i> , 2015, 33, 2354-2359.	1.7	8
498	Systems vaccinology: Enabling rational vaccine design with systems biological approaches. <i>Vaccine</i> , 2015, 33, 5294-5301.	1.7	108
499	Dispelling myths and focusing on notable concepts in HIV pathogenesis. <i>Trends in Molecular Medicine</i> , 2015, 21, 341-353.	3.5	12
500	An integrated map of HIV genome-wide variation from a population perspective. <i>Retrovirology</i> , 2015, 12, 18.	0.9	90
501	Diverse Antibody Genetic and Recognition Properties Revealed following HIV-1 Envelope Glycoprotein Immunization. <i>Journal of Immunology</i> , 2015, 194, 5903-5914.	0.4	24
502	Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. <i>Clinical and Experimental Vaccine Research</i> , 2015, 4, 1.	1.1	78

#	ARTICLE	IF	CITATIONS
503	Antibody responses to envelope glycoproteins in HIV-1 infection. <i>Nature Immunology</i> , 2015, 16, 571-576.	7.0	364
504	Antigenicity and Immunogenicity of a Trimeric Envelope Protein from an Indian Clade C HIV-1 Isolate. <i>Journal of Biological Chemistry</i> , 2015, 290, 9195-9208.	1.6	11
505	Vector-Mediated Antibody Gene Transfer for Infectious Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 149-167.	0.8	12
506	A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1126-1138.	0.5	8
507	Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays. <i>Journal of Immunology</i> , 2015, 194, 6177-6189.	0.4	9
508	CD4 mimetics sensitize HIV-1-infected cells to ADCC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2687-94.	3.3	118
509	Strategies to guide the antibody affinity maturation process. <i>Current Opinion in Virology</i> , 2015, 11, 137-147.	2.6	76
510	Variance Estimation under Two-Phase Sampling. <i>Scandinavian Journal of Statistics</i> , 2015, 42, 1078-1091.	0.9	9
511	HIV-Specific ADCC Improves After Antiretroviral Therapy and Correlates With Normalization of the NK Cell Phenotype. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 103-111.	0.9	15
512	Designing synthetic vaccines for HIV. <i>Expert Review of Vaccines</i> , 2015, 14, 815-831.	2.0	28
514	Simian Immunodeficiency Virus Infection Evades Vaccine-Elicited Antibody Responses to V2 Region. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 502-510.	0.9	9
515	The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. <i>Aids</i> , 2015, 29, 137-144.	1.0	32
516	Schistosoma mansoni Soluble Egg Antigens Enhance T Cell Responses to a Newly Identified HIV-1 Gag H-2bEpitope. <i>Vaccine Journal</i> , 2015, 22, 193-199.	3.2	3
517	The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies. , 2015, , 441-461.		0
518	The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2015, 89, 545-551.	1.5	173
519	Passively Acquired Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity in HIV-Infected Infants Is Associated with Reduced Mortality. <i>Cell Host and Microbe</i> , 2015, 17, 500-506.	5.1	137
520	Workshop report: Malaria vaccine development in Europe—preparing for the future. <i>Vaccine</i> , 2015, 33, 6137-6144.	1.7	15
521	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. <i>Journal of Virology</i> , 2015, 89, 9952-9961.	1.5	55

#	ARTICLE	IF	CITATIONS
522	A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1055-1059.	0.5	3
523	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998.	13.5	326
524	Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1036-1037.	1.4	6
525	Response to Letter to the Editor. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1038-1038.	1.4	0
526	Immune correlates of vaccine protection against HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 310rv7.	5.8	179
527	Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015). <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20150199.	1.8	3
528	Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1540-1556.	1.4	5
529	HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1060-1076.	0.5	29
530	<sc>HLA</sc> class <sc>II</sc> diversity in <sc>HIV</sc> uninfected individuals from the placebo arm of the <sc>RV144</sc> Thai vaccine efficacy trial. <i>Tissue Antigens</i> , 2015, 85, 117-126.	1.0	12
531	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. <i>Journal of Virology</i> , 2015, 89, 2507-2519.	1.5	42
532	IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1178-1186.	0.5	14
533	Defeating AIDS“advancing global health. <i>Lancet, The</i> , 2015, 386, 171-218.	6.3	234
534	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8643-8650.	1.5	42
535	Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells. <i>Journal of Immunology</i> , 2015, 195, 4861-4872.	0.4	36
536	Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. <i>Clinical and Experimental Immunology</i> , 2015, 181, 275-285.	1.1	18
537	Env“2dCD4S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1). <i>Vaccine</i> , 2015, 33, 6298-6306.	1.7	6
538	Analysis of cell-mediated immune responses in support of dengue vaccine development efforts. <i>Vaccine</i> , 2015, 33, 7083-7090.	1.7	10
539	Analysis of affinities between specific biological ligands using atomic force microscopy. <i>Analyst, The</i> , 2015, 140, 8118-8126.	1.7	7

#	ARTICLE	IF	CITATIONS
540	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8525-8539.	1.5	35
541	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. <i>EBioMedicine</i> , 2015, 2, 713-722.	2.7	13
542	Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes. <i>Journal of Virology</i> , 2015, 89, 5330-5339.	1.5	56
543	Conserved Molecular Signatures in gp120 Are Associated with the Genetic Bottleneck during Simian Immunodeficiency Virus (SIV), SIV-Human Immunodeficiency Virus (SHIV), and HIV Type 1 (HIV-1) Transmission. <i>Journal of Virology</i> , 2015, 89, 3619-3629.	1.5	22
544	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
545	Trials and Tribulations on the Path to Developing a Dengue Vaccine. <i>American Journal of Preventive Medicine</i> , 2015, 49, S334-S344.	1.6	34
546	Prospects for a Globally Effective HIV-1 Vaccine. <i>American Journal of Preventive Medicine</i> , 2015, 49, S307-S318.	1.6	29
547	Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. <i>Journal of Infectious Diseases</i> , 2015, 211, 947-955.	1.9	140
548	The Role of Human Dendritic Cells in HIV-1 Infection. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1225-1233.	0.3	47
549	Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. <i>Annual Review of Medicine</i> , 2015, 66, 423-437.	5.0	150
550	Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells. <i>Journal of Virology</i> , 2015, 89, 97-109.	1.5	42
551	Antibody-Dependent Effector Functions Against HIV Decline in Subjects Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 529-538.	1.9	28
552	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. <i>Journal of Infectious Diseases</i> , 2015, 211, 936-946.	1.9	18
553	HIV-1 prophylactic vaccines: state of the art. <i>Journal of Virus Eradication</i> , 2016, 2, 5-11.	0.3	12
555	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 17-23.	0.9	17
557	Immunity to HIV. , 2016, , 342-354.		1
558	Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1901.	1.8	14
559	Recent Insights into the HIV/AIDS Pandemic. <i>Microbial Cell</i> , 2016, 3, 450-474.	1.4	41

#	ARTICLE	IF	CITATIONS
560	Increased frequencies of CD8+CD57+T cells are associated with antibody neutralization breadth against HIV in viraemic controllers. <i>Journal of the International AIDS Society</i> , 2016, 19, 21136.	1.2	6
561	HIV Vaccine Awareness Day: sustaining the momentum. <i>Journal of the International AIDS Society</i> , 2016, 19, 21202.	1.2	1
562	Recent update in HIV vaccine development. <i>Clinical and Experimental Vaccine Research</i> , 2016, 5, 6.	1.1	26
563	Antiviral Vaccines: Challenges and Advances. , 2016, , 283-310.		6
564	Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and Persistence. <i>Viruses</i> , 2016, 8, 67.	1.5	48
565	Capsid-Targeted Viral Inactivation: A Novel Tactic for Inhibiting Replication in Viral Infections. <i>Viruses</i> , 2016, 8, 258.	1.5	8
566	Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions. <i>Vaccines</i> , 2016, 4, 17.	2.1	15
567	HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. <i>Frontiers in Immunology</i> , 2016, 7, 356.	2.2	47
568	The Significance of a Common Idiotypic (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus. <i>Frontiers in Oncology</i> , 2016, 6, 11.	1.3	2
569	Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. <i>PLoS Pathogens</i> , 2016, 12, e1005315.	2.1	220
570	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. <i>PLoS Pathogens</i> , 2016, 12, e1005817.	2.1	119
571	Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?. <i>PLoS Biology</i> , 2016, 14, e1002372.	2.6	12
572	Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. <i>PLoS ONE</i> , 2016, 11, e0155702.	1.1	22
573	Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response. <i>PLoS ONE</i> , 2016, 11, e0157353.	1.1	10
574	NK Cells Expressing the Inhibitory Killer Immunoglobulin-Like Receptors (iKIR) KIR2DL1, KIR2DL3 and KIR3DL1 Are Less Likely to Be CD16+ than Their iKIR Negative Counterparts. <i>PLoS ONE</i> , 2016, 11, e0164517.	1.1	5
575	Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). <i>PLoS ONE</i> , 2016, 11, e0166393.	1.1	14
576	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. <i>PLoS Pathogens</i> , 2016, 12, e1005537.	2.1	51
577	Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. <i>Aids</i> , 2016, 30, 1005-1014.	1.0	18



#	ARTICLE	IF	CITATIONS
578	An HIV Vaccine. JAMA - Journal of the American Medical Association, 2016, 316, 143.	3.8	24
579	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. Emerging Microbes and Infections, 2016, 5, 1-12.	3.0	24
580	An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. Vaccine Journal, 2016, 23, 618-627.	3.2	7
581	Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition. Aids, 2016, 30, 1703-1712.	1.0	21
582	Combining biomarkers linearly and nonlinearly for classification using the area under the ROC curve. Statistics in Medicine, 2016, 35, 3792-3809.	0.8	15
583	Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. Statistics in Medicine, 2016, 35, 3745-3759.	0.8	8
584	Functional advantage of educated KIR2DL1+ natural killer cells for anti-HIV-1 antibody-dependent activation. Clinical and Experimental Immunology, 2016, 184, 101-109.	1.1	17
585	Systems biology and the quest for correlates of protection to guide the development of an HIV vaccine. Current Opinion in Immunology, 2016, 41, 91-97.	2.4	10
586	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 184-188.	0.9	1
587	The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?. Molecular Therapy, 2016, 24, 1896-1897.	3.7	0
588	Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. Nature Communications, 2016, 7, 12131.	5.8	14
589	Predicting Overall Vaccine Efficacy in a New Setting by Re-calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy. Epidemiologic Methods, 2016, 5, 93-112.	0.8	13
590	A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice. Scientific Reports, 2016, 6, 29131.	1.6	17
591	Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. Journal of Immunology, 2016, 197, 4603-4612.	0.4	44
592	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	3.7	41
593	Designing optimal HIV-vaccine T-cell responses. Current Opinion in HIV and AIDS, 2016, 11, 593-600.	1.5	16
594	Therapeutic vaccines and immunological intervention in HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 576-584.	1.5	40
595	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine, 2016, 14, 97-111.	2.7	47

#	ARTICLE	IF	CITATIONS
596	Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region. <i>Structure</i> , 2016, 24, 697-709.	1.6	46
597	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. <i>Journal of Virology</i> , 2016, 90, 5315-5328.	1.5	12
598	Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits. <i>Vaccine</i> , 2016, 34, 2444-2452.	1.7	3
599	Exploiting Mucosal Immunity for Antiviral Vaccines. <i>Annual Review of Immunology</i> , 2016, 34, 575-608.	9.5	109
600	Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. <i>Vaccine</i> , 2016, 34, 2713-2721.	1.7	23
601	Accelerated actin filament polymerization from microtubule plus ends. <i>Science</i> , 2016, 352, 1004-1009.	6.0	172
602	Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines. <i>Virology</i> , 2016, 489, 141-150.	1.1	17
603	In men at risk of HIV infection, IgM, IgG1, IgG3, and IgA reach the human foreskin epidermis. <i>Mucosal Immunology</i> , 2016, 9, 798-808.	2.7	15
604	Search continues for a CMV vaccine for transplant recipients. <i>Lancet Haematology</i> , the, 2016, 3, e58-e59.	2.2	3
605	Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. <i>Journal of Infectious Diseases</i> , 2016, 213, 1946-1954.	1.9	14
606	Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. <i>Journal of Virology</i> , 2016, 90, 6127-6139.	1.5	117
607	Transformation Model Choice in Nonlinear Regression Analysis of Fluorescence-Based Serial Dilution Assays. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 1-11.	0.6	7
608	Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. <i>Science</i> , 2016, 352, 1001-1004.	6.0	302
609	Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. <i>Vaccine Journal</i> , 2016, 23, 496-506.	3.2	24
610	HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. <i>Journal of Virology</i> , 2016, 90, 9855-9861.	1.5	12
611	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <i>Journal of Immunology</i> , 2016, 197, 2726-2737.	0.4	34
612	Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PC9 antibody. <i>Molecular Immunology</i> , 2016, 77, 14-25.	1.0	11
613	Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 3202-3211.	1.4	9

#	ARTICLE	IF	CITATIONS
614	Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 823-834.	21.5	51
615	Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. <i>Journal of Virology</i> , 2016, 90, 11007-11019.	1.5	41
616	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. <i>Journal of Virology</i> , 2016, 90, 8644-8660.	1.5	13
617	First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. <i>Journal of Immunology</i> , 2016, 197, 1979-1988.	0.4	1
618	Antibody-Dependent Cellular Cytotoxicity Activity of Effector Cells from HIV-Infected Elite and Viral Controllers. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1079-1088.	0.5	15
619	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2016, 35, 217-226.	0.8	9
620	NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1089-1096.	0.5	31
621	Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study. <i>BMC Medicine</i> , 2016, 14, 76.	2.3	55
622	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16068.	1.8	48
623	Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. <i>Journal of Virology</i> , 2016, 90, 10993-11006.	1.5	33
624	Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India. <i>Virology</i> , 2016, 499, 105-113.	1.1	7
625	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. <i>EBioMedicine</i> , 2016, 12, 208-218.	2.7	65
626	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. <i>Journal of Virology</i> , 2016, 90, 10362-10378.	1.5	26
627	HIV Envelope gp120 Alters T Cell Receptor Mobilization in the Immunological Synapse of Uninfected CD4 T Cells and Augments T Cell Activation. <i>Journal of Virology</i> , 2016, 90, 10513-10526.	1.5	10
628	Remaining Challenges in Pediatric HIV-1 Infection. <i>Current Pediatrics Reports</i> , 2016, 4, 63-73.	1.7	1
629	Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice. <i>Vaccine</i> , 2016, 34, 6276-6284.	1.7	4
630	Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses. <i>Scientific Reports</i> , 2016, 6, 36658.	1.6	11
631	Elimination of HIV-1-infected cells by broadly neutralizing antibodies. <i>Nature Communications</i> , 2016, 7, 10844.	5.8	201

#	ARTICLE	IF	CITATIONS
632	Antibody-dependent CD56+ T cell responses are functionally impaired in long-term HIV-1 infection. <i>Retrovirology</i> , 2016, 13, 76.	0.9	6
633	Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240. <i>Scientific Reports</i> , 2016, 6, 36685.	1.6	31
634	Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. <i>Journal of Virology</i> , 2016, 90, 8487-8495.	1.5	7
635	Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1187-1197.	0.5	1
636	Modulating Antibody Functionality in Infectious Disease and Vaccination. <i>Trends in Molecular Medicine</i> , 2016, 22, 969-982.	3.5	71
637	Evaluating and comparing biomarkers with respect to the area under the receiver operating characteristics curve in two-phase case-control studies. <i>Biostatistics</i> , 2016, 17, 499-522.	0.9	13
638	HIV-specific Th2 and Th17 responses predict HIV vaccine protection efficacy. <i>Scientific Reports</i> , 2016, 6, 28129.	1.6	10
639	Modeling HIV vaccine trials of the future. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 620-627.	1.5	5
640	Lessons from HIV-1 vaccine efficacy trials. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 607-613.	1.5	21
641	Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice. <i>Journal of Translational Medicine</i> , 2016, 14, 343.	1.8	10
642	Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques. <i>Virology Journal</i> , 2016, 13, 200.	1.4	11
643	Cell and gene therapy strategies to eradicate HIV reservoirs. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 442-449.	1.5	21
644	Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. <i>AIDS Research and Therapy</i> , 2016, 13, 41.	0.7	3
645	Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. <i>Aids</i> , 2016, 30, 2405-2414.	1.0	14
646	The first 24h. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 561-568.	1.5	10
647	Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 614-619.	1.5	20
648	Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates. <i>Aids</i> , 2016, 30, 2551-2553.	1.0	7
649	Assessment of Anti-HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 130-137.	0.9	12

#	ARTICLE	IF	CITATIONS
650	New concepts in HIV-1 vaccine development. <i>Current Opinion in Immunology</i> , 2016, 41, 39-46.	2.4	77
651	Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. <i>Current Opinion in Immunology</i> , 2016, 42, 56-64.	2.4	30
652	Viral vectors as vaccine platforms: from immunogenicity to impact. <i>Current Opinion in Immunology</i> , 2016, 41, 47-54.	2.4	137
653	Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2016, 90, 7285-7302.	1.5	30
654	Cell-targeting antibodies in immunity to Ebola. <i>Pathogens and Disease</i> , 2016, 74, ftw021.	0.8	11
655	Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. <i>Journal of Virology</i> , 2016, 90, 813-828.	1.5	34
656	Broadly Neutralizing Antibodies: Magic Bullets against HIV?. <i>Immunity</i> , 2016, 44, 1253-1254.	6.6	3
657	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	15.2	197
658	A new cell line for high throughput HIV-specific antibody-dependent cellular cytotoxicity (ADCC) and cell-to-cell virus transmission studies. <i>Journal of Immunological Methods</i> , 2016, 433, 51-58.	0.6	37
659	Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-Mediated Specific Immune Responses against HIV-1. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1172-1181.	0.3	17
660	B cells in HIV pathogenesis. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 23-30.	1.3	10
661	Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. <i>Expert Review of Vaccines</i> , 2016, 15, 719-729.	2.0	30
662	The Yin and Yang of ADCC-Mediating Antibodies. <i>EBioMedicine</i> , 2016, 3, 10-11.	2.7	2
663	Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy. <i>Virology</i> , 2016, 487, 75-84.	1.1	6
664	Biologics to Treat Substance Use Disorders. , 2016, , .		3
665	How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. <i>Expert Review of Vaccines</i> , 2016, 15, 295-311.	2.0	48
666	Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1 "Infected Individuals from Guinea-Bissau and Denmark. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 434-442.	0.5	6
667	Approaches to preventative and therapeutic HIV vaccines. <i>Current Opinion in Virology</i> , 2016, 17, 104-109.	2.6	72

#	ARTICLE	IF	CITATIONS
668	The improved antibody response against HIV-1 after a vaccination based on intrastuctural help is complemented by functional CD8+ T cell responses. <i>Vaccine</i> , 2016, 34, 1744-1751.	1.7	9
669	Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge. <i>Virology</i> , 2016, 489, 1-11.	1.1	2
670	NK Cells in HIV Disease. <i>Current HIV/AIDS Reports</i> , 2016, 13, 85-94.	1.1	114
671	High-Resolution Longitudinal Study of HIV-1 Env Vaccine Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. <i>Journal of Immunology</i> , 2016, 196, 3729-3743.	0.4	26
672	Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. <i>Mucosal Immunology</i> , 2016, 9, 1584-1595.	2.7	92
673	Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines A review from a regulatory perspective. <i>Biologicals</i> , 2016, 44, 90-110.	0.5	5
674	Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. <i>Journal of Virology</i> , 2016, 90, 636-649.	1.5	70
675	Polyvinylpyrrolidone Poly(ethylene glycol) Modified Silver Nanorods Can Be a Safe, Noncarrier Adjuvant for HIV Vaccine. <i>ACS Nano</i> , 2016, 10, 3589-3596.	7.3	39
676	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	1.5	22
677	Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. <i>Immunity</i> , 2016, 44, 167-178.	6.6	104
678	Engineering broadly neutralizing antibodies for HIV prevention and therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 157-173.	6.6	17
679	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. <i>Mucosal Immunology</i> , 2016, 9, 821-833.	2.7	22
680	HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response. <i>Expert Review of Vaccines</i> , 2016, 15, 709-717.	2.0	7
681	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. <i>Journal of Virology</i> , 2016, 90, 5031-5046.	1.5	38
682	HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , 2016, 19, 292-303.	5.1	143
683	New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. <i>Expert Review of Vaccines</i> , 2016, 15, 1015-1027.	2.0	9
684	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016, 17, 57-65.	2.6	14
685	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016, 90, 4951-4965.	1.5	23

#	ARTICLE	IF	CITATIONS
686	Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2016, 90, 2993-3002.	1.5	72
687	Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned. <i>Biologicals</i> , 2016, 44, 73-89.	0.5	17
688	Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination. <i>Vaccine Journal</i> , 2016, 23, 84-94.	3.2	35
689	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. <i>Journal of Virology</i> , 2016, 90, 2021-2030.	1.5	53
690	In situ formation of peptidic nanofibers can fundamentally optimize the quality of immune responses against HIV vaccine. <i>Nanoscale Horizons</i> , 2016, 1, 135-143.	4.1	24
691	A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract. <i>Mucosal Immunology</i> , 2016, 9, 1340-1352.	2.7	23
692	A systems approach to HIV-1 vaccines. <i>Nature Biotechnology</i> , 2016, 34, 44-46.	9.4	2
693	Getting rid of PERVs. <i>Nature Biotechnology</i> , 2016, 34, 46-46.	9.4	3
694	Anti-Infectious Human Vaccination in Historical Perspective. <i>International Reviews of Immunology</i> , 2016, 35, 260-290.	1.5	18
695	The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostrum B cells. <i>Mucosal Immunology</i> , 2016, 9, 414-427.	2.7	19
696	Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses. <i>Expert Review of Vaccines</i> , 2016, 15, 119-127.	2.0	8
697	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550.	1.9	28
698	Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2016, 90, 670-681.	1.5	39
699	Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. <i>Mucosal Immunology</i> , 2016, 9, 13-23.	2.7	33
700	Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling. <i>Lifetime Data Analysis</i> , 2017, 23, 136-159.	0.4	5
701	Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. <i>Mucosal Immunology</i> , 2017, 10, 228-237.	2.7	34
702	Current views on the potential for development of a HIV vaccine. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 295-303.	1.4	23
703	DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. <i>Vaccine</i> , 2017, 35, 929-937.	1.7	7

#	ARTICLE	IF	CITATIONS
704	Systems serology for evaluation of <scp>HIV</scp> vaccine trials. Immunological Reviews, 2017, 275, 262-270.	2.8	69
705	<scp>HIV</scp> antibodies for treatment of <scp>HIV</scp> infection. Immunological Reviews, 2017, 275, 313-323.	2.8	59
706	Complex immune correlates of protection in <scp>HIV</scp> vaccine efficacy trials. Immunological Reviews, 2017, 275, 245-261.	2.8	95
707	The quest for an antibody-based <scp>HIV</scp> vaccine. Immunological Reviews, 2017, 275, 5-10.	2.8	91
708	Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies. Journal of Virology, 2017, 91, .	1.5	63
709	Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. Vaccine, 2017, 35, 1184-1193.	1.7	9
710	Genetic and structural analyses of affinity maturation in the humoral response to <scp>HIV</scp>. Immunological Reviews, 2017, 275, 129-144.	2.8	17
711	Polyvalent vaccine approaches to combat <scp>HIV</scp> diversity. Immunological Reviews, 2017, 275, 230-244.	2.8	46
712	Germline-targeting immunogens. Immunological Reviews, 2017, 275, 203-216.	2.8	105
713	Immunologic characteristics of <scp>HIV</scp>-infected individuals who make broadly neutralizing antibodies. Immunological Reviews, 2017, 275, 62-78.	2.8	58
714	Survivors Remorse: antibody-mediated protection against <scp>HIV</scp>. Immunological Reviews, 2017, 275, 271-284.	2.8	25
715	Antibody gene transfer with adeno-associated viral vectors as a method for <scp>HIV</scp> prevention. Immunological Reviews, 2017, 275, 324-333.	2.8	51
716	Tfh cells and <scp>HIV</scp> bnAbs, an immunodominance model of the <scp>HIV</scp> neutralizing antibody generation problem. Immunological Reviews, 2017, 275, 49-61.	2.8	167
717	Ontogeny-based immunogens for the induction of V2-directed <scp>HIV</scp> broadly neutralizing antibodies. Immunological Reviews, 2017, 275, 217-229.	2.8	27
718	Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display. AIDS Research and Human Retroviruses, 2017, 33, 869-879.	0.5	4
719	Antibody-dependent cellular cytotoxicity and influenza virus. Current Opinion in Virology, 2017, 22, 89-96.	2.6	60
720	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. Journal of Immunology, 2017, 198, 1047-1055.	0.4	7
721	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. Journal of Virology, 2017, 91, .	1.5	52



#	ARTICLE	IF	CITATIONS
722	Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner. <i>Journal of Virology</i> , 2017, 91, .	1.5	48
723	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. <i>Journal of Virology</i> , 2017, 91, .	1.5	73
724	A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1466-1474.	1.4	5
725	Vaccine nanoparticles for protection against HIV infection. <i>Nanomedicine</i> , 2017, 12, 673-682.	1.7	22
726	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	29
727	Progress in HIV vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1018-1030.	1.4	80
728	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	1.5	26
729	A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. <i>Scientific Reports</i> , 2017, 7, 1057.	1.6	10
730	Lessons learned from human HIV vaccine trials. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 216-221.	1.5	31
731	Distinct Roles of Vaccinia Virus NF- $\beta$ B Inhibitor Proteins A52, B15, and K7 in the Immune Response. <i>Journal of Virology</i> , 2017, 91, .	1.5	31
732	Systematic Synthesis and Binding Study of HIV V3 Glycopeptides Reveal the Fine Epitopes of Several Broadly Neutralizing Antibodies. <i>ACS Chemical Biology</i> , 2017, 12, 1566-1575.	1.6	24
733	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1255-1263.	1.9	57
734	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	5
735	Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach. <i>Immunity</i> , 2017, 46, 804-817.e7.	6.6	107
736	Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. <i>Aids</i> , 2017, 31, 1505-1517.	1.0	22
737	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant. <i>Npj Vaccines</i> , 2017, 2, 13.	2.9	34
738	Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses. <i>Vaccine</i> , 2017, 35, 2582-2591.	1.7	1
739	A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. <i>Virology</i> , 2017, 507, 242-256.	1.1	5

#	ARTICLE	IF	CITATIONS
740	Guiding the long way to broad HIV neutralization. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 257-264.	1.5	15
741	Universal antiretroviral regimens. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 343-350.	1.5	30
742	Dimeric Fc $\gamma$ 3 Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fc $\gamma$ 3 Receptor Antibodies Induced by the RV144 Vaccine Trial. <i>Journal of Immunology</i> , 2017, 199, 816-826.	0.4	43
743	Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer. <i>Journal of Virology</i> , 2017, 91, .	1.5	35
744	Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response. <i>Journal of Virology</i> , 2017, 91, .	1.5	10
745	Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 209-215.	1.5	11
746	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. <i>Protein and Cell</i> , 2017, 8, 861-877.	4.8	53
747	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	6.6	286
748	Determinants of HIV-1 CD4-Independent Brain Adaptation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 209-218.	0.9	4
749	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	5.8	137
750	Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir. <i>Journal of Virology</i> , 2017, 91, .	1.5	33
751	Humoral responses against HIV in male genital tract. <i>Aids</i> , 2017, 31, 1055-1064.	1.0	1
752	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1376-1385.	1.9	59
753	Adjuvants. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 278-284.	1.5	27
754	How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 229-240.	1.5	66
755	Progress in HIV-1 antibody research using humanized mice. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 285-293.	1.5	12
756	Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients. <i>Clinical and Experimental Immunology</i> , 2017, 189, 92-102.	1.1	6
757	BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	40

#	ARTICLE	IF	CITATIONS
758	In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses. <i>Vaccine</i> , 2017, 35, 2042-2051.	1.7	9
759	SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials. <i>Bioinformatics</i> , 2017, 33, 2386-2388.	1.8	4
760	Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 345-353.	0.9	12
761	Combining biomarkers for classification with covariate adjustment. <i>Statistics in Medicine</i> , 2017, 36, 2347-2362.	0.8	8
762	Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1433-1440.	1.4	3
763	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 859-868.	0.5	18
764	Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 410-423.	0.5	38
765	Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5 $\alpha$ Restrictive Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	70
766	Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 880-888.	0.5	22
767	Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity. <i>Mucosal Immunology</i> , 2017, 10, 814-826.	2.7	13
768	The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir. <i>Current Topics in Microbiology and Immunology</i> , 2017, 417, 43-67.	0.7	3
769	Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost. <i>Journal of Infectious Diseases</i> , 2017, 216, 1080-1090.	1.9	23
770	Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity. <i>MBio</i> , 2017, 8, .	1.8	32
771	Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex. <i>Journal of Virology</i> , 2017, 91, .	1.5	19
772	Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. <i>Scientific Reports</i> , 2017, 7, 12655.	1.6	50
773	DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers. <i>Journal of Immunology</i> , 2017, 199, 3437-3452.	0.4	7
774	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 <sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , 2017, 24, .	3.2	33
775	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	1.5	23

#	ARTICLE	IF	CITATIONS
776	Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region. <i>Structure</i> , 2017, 25, 1719-1731.e4.	1.6	31
777	HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	1.5	15
778	Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models. <i>Expert Review of Vaccines</i> , 2017, 16, 973-985.	2.0	27
779	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. <i>Vaccine Journal</i> , 2017, 24, .	3.2	28
780	Extracellular Matrix Proteins Mediate HIV-1 gp120 Interactions with $\hat{I}^{\pm 4}$ $\hat{I}^{\pm 7}$ . <i>Journal of Virology</i> , 2017, 91, .	1.5	8
781	Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs. <i>Journal of Infection</i> , 2017, 75, 555-571.	1.7	29
782	Natural killer cells in HIV-1 infection and therapy. <i>Aids</i> , 2017, 31, 2317-2330.	1.0	90
783	Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2996-3009.	1.4	7
784	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	87
785	Protection against HIV Acquisition in the RV144 Trial. <i>Journal of Virology</i> , 2017, 91, .	1.5	19
786	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. <i>Cell</i> , 2017, 170, 637-648.e10.	13.5	111
787	Comprehensive Characterization of Humoral Correlates of Human Immunodeficiency Virus 1 Superinfection Acquisition in High-risk Kenyan Women. <i>EBioMedicine</i> , 2017, 18, 216-224.	2.7	15
788	HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. <i>Journal of Virology</i> , 2017, 91, .	1.5	59
789	Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. <i>Journal of Virology</i> , 2017, 91, .	1.5	8
790	Immune correlates of protection for dengue: State of the art and research agenda. <i>Vaccine</i> , 2017, 35, 4659-4669.	1.7	81
791	Intrastructural help. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 272-277.	1.5	15
792	Antibody-mediated immune exclusion of HIV. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 222-228.	1.5	10
793	Novel Concepts for HIV Vaccine Vector Design. <i>MSphere</i> , 2017, 2, .	1.3	11

#	ARTICLE	IF	CITATIONS
794	HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-4.	3.0	2
795	Patterns of conserved gp120 epitope presentation on attached HIV-1 virions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9893-E9902.	3.3	12
796	Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus. <i>Annual Review of Virology</i> , 2017, 4, 491-510.	3.0	2
797	Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals. <i>Vaccine Journal</i> , 2017, 24, .	3.2	14
798	Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2849-2858.	1.4	5
799	Working towards dengue as a vaccine-preventable disease: challenges and opportunities. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1193-1199.	1.4	15
800	Prospecting for an HIV vaccine. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2017, 3, 6.	0.9	7
801	Model-Robust Inference for Continuous Threshold Regression Models. <i>Biometrics</i> , 2017, 73, 452-462.	0.8	27
802	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. <i>Journal of Virology</i> , 2017, 91, .	1.5	29
803	Estimation of Stratified Mark-Specific Proportional Hazards Models Under Two-Phase Sampling with Application to HIV Vaccine Efficacy Trials. <i>Statistics in Biosciences</i> , 2017, 9, 259-283.	0.6	7
804	HIV Vaccines. , 2017, , 829-834.e1.		0
805	Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials. <i>Biostatistics</i> , 2017, 18, 230-243.	0.9	8
806	Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2017, 292, 278-291.	1.6	18
807	Natural infection as a blueprint for rational HIV vaccine design. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 229-236.	1.4	3
808	Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. <i>Journal of Infectious Diseases</i> , 2017, 215, S152-S159.	1.9	22
809	A Role for Fc-Mediated Humoral Immunity in Reducing HIV Transmission Rates between HIV Serodiscordant Heterosexual Couples. <i>EBioMedicine</i> , 2017, 26, 2-3.	2.7	1
810	Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination. <i>Molecular Biology</i> , 2017, 51, 819-829.	0.4	1
811	Broadly Neutralizing Antibodies. , 2017, , 3-21.		2

#	ARTICLE	IF	CITATIONS
812	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. <i>Blood Advances</i> , 2017, 1, 2329-2342.	2.5	90
813	Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era. <i>Viruses</i> , 2017, 9, 281.	1.5	21
814	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
815	Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. <i>Frontiers in Immunology</i> , 2017, 7, 661.	2.2	11
816	Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein. <i>Frontiers in Immunology</i> , 2017, 8, 5.	2.2	22
817	Cytotoxic CD4 T Cells—Friend or Foe during Viral Infection?. <i>Frontiers in Immunology</i> , 2017, 8, 19.	2.2	177
818	A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. <i>Frontiers in Immunology</i> , 2017, 8, 149.	2.2	35
819	Role of Natural Killer Cells in HIV-Associated Malignancies. <i>Frontiers in Immunology</i> , 2017, 8, 315.	2.2	5
820	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. <i>Frontiers in Immunology</i> , 2017, 8, 595.	2.2	20
821	Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design. <i>Frontiers in Immunology</i> , 2017, 8, 780.	2.2	23
822	Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity. <i>Frontiers in Immunology</i> , 2017, 8, 1033.	2.2	17
823	The Significance of Type-I Interferons in the Pathogenesis and Therapy of Human Immunodeficiency Virus 1 Infection. <i>Frontiers in Immunology</i> , 2017, 8, 1431.	2.2	23
824	Mucosal IgA Responses: Damaged in Established HIV Infection—Yet, Effective Weapon against HIV Transmission. <i>Frontiers in Immunology</i> , 2017, 8, 1581.	2.2	30
825	Non-Neutralizing Antibodies Directed against HIV and Their Functions. <i>Frontiers in Immunology</i> , 2017, 8, 1590.	2.2	48
826	Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. <i>Frontiers in Immunology</i> , 2017, 8, 1655.	2.2	22
827	Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. <i>Frontiers in Immunology</i> , 2017, 8, 1883.	2.2	13
828	Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1. <i>Frontiers in Microbiology</i> , 2017, 8, 2091.	1.5	11
829	Humanized Immunoglobulin Mice. <i>Advances in Immunology</i> , 2017, 134, 235-352.	1.1	14

#	ARTICLE	IF	CITATIONS
830	Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques. PLoS ONE, 2017, 12, e0172524.	1.1	2
831	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE, 2017, 12, e0176428.	1.1	12
832	HIV-1 adaptation to NK cell-mediated immune pressure. PLoS Pathogens, 2017, 13, e1006361.	2.1	11
833	Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. PLoS Pathogens, 2017, 13, e1006793.	2.1	20
834	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	5.8	76
835	Systems serology: profiling vaccine induced humoral immunity against HIV. Retrovirology, 2017, 14, 57.	0.9	75
836	Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design. AIDS Research and Therapy, 2017, 14, 48.	0.7	13
837	Unlocking HIV-1 Env: implications for antibody attack. AIDS Research and Therapy, 2017, 14, 42.	0.7	8
838	RNA flow cytometric FISH for investigations into HIV immunology, vaccination and cure strategies. AIDS Research and Therapy, 2017, 14, 40.	0.7	10
839	Natural killer (NK) cell receptor-HLA ligand genotype combinations associated with protection from HIV infection: investigation of how protective genotypes influence anti HIV NK cell functions. AIDS Research and Therapy, 2017, 14, 38.	0.7	4
840	Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines. AIDS Research and Therapy, 2017, 14, 47.	0.7	9
841	Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. AIDS Research and Therapy, 2017, 14, 55.	0.7	20
842	Conserved HIV Epitopes for an Effective HIV Vaccine. Journal of Clinical & Cellular Immunology, 2017, 08, .	1.5	23
843	Fc functional antibodies in humans with severe H7N9 and seasonal influenza. JCI Insight, 2017, 2, .	2.3	39
844	Systems Vaccinology. , 2017, , 101-112.		0
845	Methodical Considerations. , 2017, , 137-162.		0
846	Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field. Current HIV Research, 2017, 15, 202-215.	0.2	28
847	Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions. Journal of Virology, 2018, 92, .	1.5	17

#	ARTICLE	IF	CITATIONS
848	Vaccinating for natural killer cell effector functions. <i>Clinical and Translational Immunology</i> , 2018, 7, e1010.	1.7	29
849	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	1.5	46
850	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 436-447.	1.1	18
851	Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections. <i>Journal of Virology</i> , 2018, 92, .	1.5	60
852	Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6273-6278.	3.3	101
853	Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. <i>Scientific Reports</i> , 2018, 8, 6066.	1.6	17
854	The roles of resident, central and effector memory CD4 <sup>+</sup> T cells in protective immunity following infection or vaccination. <i>Immunology</i> , 2018, 154, 574-581.	2.0	71
855	Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. <i>Nature Communications</i> , 2018, 9, 1212.	5.8	44
856	Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity. <i>Aids</i> , 2018, 32, 1207-1217.	1.0	31
857	High-resolution definition of humoral immune response correlates of effective immunity against HIV. <i>Molecular Systems Biology</i> , 2018, 14, e7881.	3.2	37
858	Inflammation weakens HIV prevention. <i>Nature Medicine</i> , 2018, 24, 384-385.	15.2	6
859	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	1.9	35
860	Analysis of generalized semiparametric regression models for cumulative incidence functions with missing covariates. <i>Computational Statistics and Data Analysis</i> , 2018, 122, 59-79.	0.7	3
861	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	1.5	10
862	Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity. <i>Journal of Immunology</i> , 2018, 200, ji1701523.	0.4	11
863	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	1.9	32
864	High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses. <i>Journal of Virology</i> , 2018, 92, .	1.5	5
865	Integrin $\alpha 4 \beta 7$ expression on peripheral blood CD4 <sup>+</sup> T cells predicts HIV acquisition and disease progression outcomes. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	85



#	ARTICLE	IF	CITATIONS
866	Neutralization tiers of HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 128-136.	1.5	89
867	Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. <i>Journal of Immunological Methods</i> , 2018, 454, 48-58.	0.6	17
868	A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	30
869	Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029124.	2.3	12
870	Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. <i>Scientific Reports</i> , 2018, 8, 542.	1.6	30
871	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	1.5	45
872	Postvaccination C-Reactive Protein and C5/gp41 <sup>732-744</sup> Antibody Level Fold-Changes Over Baseline Are Independent Predictors of Therapeutic HIV Vaccine Effect in a Phase 2 Clinical Study of Vacc-4x. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 307-313.	0.5	10
873	What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM. <i>EBioMedicine</i> , 2018, 27, 51-60.	2.7	8
874	Passive and active antibody studies in primates to inform HIV vaccines. <i>Expert Review of Vaccines</i> , 2018, 17, 1-18.	2.0	36
875	Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome. <i>Viral Immunology</i> , 2018, 31, 124-132.	0.6	4
876	Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Virology</i> , 2018, 92, .	1.5	56
877	Impact of HLA Allele-KIR Pairs on Disease Outcome in HIV-Infected Thai Population. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 356-361.	0.9	9
878	Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. <i>Journal of Immunological Methods</i> , 2018, 457, 41-52.	0.6	51
879	Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. <i>Journal of Virology</i> , 2018, 92, .	1.5	51
880	Nonhuman primate models of human viral infections. <i>Nature Reviews Immunology</i> , 2018, 18, 390-404.	10.6	151
881	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028902.	2.3	31
882	Beyond binding: antibody effector functions in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 46-61.	10.6	516
883	Induction of vaginal-resident HIV-specific CD8 T cells with mucosal prime-boost immunization. <i>Mucosal Immunology</i> , 2018, 11, 994-1007.	2.7	41

#	ARTICLE	IF	CITATIONS
884	Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 193-205.	0.5	17
885	HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. <i>Journal of Virology</i> , 2018, 92, .	1.5	36
886	Immunization with Clinical HIV-1 Env Proteins Induces Broad Antibody Dependent Cellular Cytotoxicity-Mediating Antibodies in a Rabbit Vaccination Model. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 206-217.	0.5	5
887	Impact of HIV-1 Envelope Conformation on ADCC Responses. <i>Trends in Microbiology</i> , 2018, 26, 253-265.	3.5	64
888	Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. <i>Virology</i> , 2018, 514, 106-117.	1.1	29
889	Anti-HIV-1 antibody-dependent cellular cytotoxicity. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 160-166.	1.5	25
890	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
891	Prospects from systems serology research. <i>Immunology</i> , 2018, 153, 279-289.	2.0	62
892	The microbiome and HIV persistence. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 61-68.	1.5	35
893	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. <i>PLoS ONE</i> , 2018, 13, e0208345.	1.1	8
894	Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines. <i>Frontiers in Immunology</i> , 2018, 9, 2441.	2.2	22
895	Viral-Induced Enhanced Disease Illness. <i>Frontiers in Microbiology</i> , 2018, 9, 2991.	1.5	103
896	Defensive Driving: Directing HIV-1 Vaccine-Induced Humoral Immunity to the Mucosa with Chemokine Adjuvants. <i>Journal of Immunology Research</i> , 2018, 2018, 1-14.	0.9	7
897	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	2.0	26
898	Antibody-dependent cellular cytotoxicity in HIV infection. <i>Aids</i> , 2018, 32, 2439-2451.	1.0	67
899	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. <i>PLoS ONE</i> , 2018, 13, e0194266.	1.1	14
900	Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation. <i>MBio</i> , 2018, 9, .	1.8	15
901	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , 2018, 25, 3123-3135.e6.	2.9	23

#	ARTICLE	IF	CITATIONS
902	The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256. <i>PLoS ONE</i> , 2018, 13, e0208310.	1.1	22
903	Molecular epidemiology of a primarily MSM acute HIV-1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia. <i>Journal of the International AIDS Society</i> , 2018, 21, e25204.	1.2	14
904	Brief Report: The Anti-HIV-1 ADCC-Mediating Antibodies From Cervicovaginal Secretions of HIV-Infected Women Have an Ability to Mediate Lysing of Autologous CD4+ HIV-Infected Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 277-282.	0.9	7
905	Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. <i>PLoS ONE</i> , 2018, 13, e0206838.	1.1	25
906	CMV Primes Functional Alternative Signaling in Adaptive $\gamma$ NK Cells but Is Subverted by Lentivirus Infection in Rhesus Macaques. <i>Cell Reports</i> , 2018, 25, 2766-2774.e3.	2.9	32
907	Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine. <i>Viruses</i> , 2018, 10, 277.	1.5	10
908	Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity. <i>Frontiers in Immunology</i> , 2018, 9, 2613.	2.2	7
909	Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates. <i>Npj Vaccines</i> , 2018, 3, 46.	2.9	24
910	Self-Assembling Protein Nanoparticles: implications for HIV-1 vaccine development. <i>Nanomedicine</i> , 2018, 13, 2121-2125.	1.7	9
911	Development of a Stable MGAT1 $\alpha$ CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2313.	2.2	2
912	Measuring the ability of HIV-specific antibodies to mediate trogocytosis. <i>Journal of Immunological Methods</i> , 2018, 463, 71-83.	0.6	32
913	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. <i>PLoS ONE</i> , 2018, 13, e0196397.	1.1	14
914	The Early Antibody-Dependent Cell-Mediated Cytotoxicity Response Is Associated With Lower Viral Set Point in Individuals With Primary HIV Infection. <i>Frontiers in Immunology</i> , 2018, 9, 2322.	2.2	25
915	NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2290.	2.2	79
916	Common helical V1V2 conformations of HIV-1 Envelope expose the $\pm 4^{\circ} 7$ binding site on intact virions. <i>Nature Communications</i> , 2018, 9, 4489.	5.8	24
918	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
919	Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways. <i>Viruses</i> , 2018, 10, 7.	1.5	9
920	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. <i>Nature Medicine</i> , 2018, 24, 1590-1598.	15.2	129

#	ARTICLE	IF	CITATIONS
921	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to $\hat{I}\pm 4\hat{I}^27$ . PLoS Pathogens, 2018, 14, e1007278.	2.1	29
922	Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India. PLoS ONE, 2018, 13, e0203037.	1.1	11
923	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. Aids, 2018, 32, 1749-1761.	1.0	11
924	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nature Medicine, 2018, 24, 847-856.	15.2	65
925	Preventing Mother-to-Child Transmission (PMTCT): Prevention of HIV. , 2018, , 1698-1704.		0
926	Frequencies of Circulating Th1-Biased T Follicular Helper Cells in Acute HIV-1 Infection Correlate with the Development of HIV-Specific Antibody Responses and Lower Set Point Viral Load. Journal of Virology, 2018, 92, .	1.5	46
928	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV,the, 2018, 5, e366-e378.	2.1	86
929	Towards conformational fidelity of a quaternary HIV-1 epitope: computational design and directed evolution of a minimal V1V2 antigen. Protein Engineering, Design and Selection, 2018, 31, 121-133.	1.0	8
930	Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?. Retrovirology, 2018, 15, 52.	0.9	29
931	CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication. Retrovirology, 2018, 15, 46.	0.9	37
932	Control of Heterologous Simian Immunodeficiency Virus SIV <sub>smE660</sub> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. Journal of Virology, 2018, 92, .	1.5	39
933	Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite anthelmintic treatment and increases helminth-associated pathology in a mouse model. PLoS Pathogens, 2018, 14, e1007182.	2.1	22
935	Advances in HIV-1 Vaccine Development. Viruses, 2018, 10, 167.	1.5	56
936	Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. Journal of Virology, 2018, 92, .	1.5	26
937	Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies. PLoS ONE, 2018, 13, e0196370.	1.1	16
938	Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production. PLoS ONE, 2018, 13, e0197656.	1.1	17
939	IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis. Frontiers in Immunology, 2018, 9, 244.	2.2	34
940	Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans. Frontiers in Immunology, 2018, 9, 301.	2.2	18

#	ARTICLE	IF	CITATIONS
941	Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries. <i>Frontiers in Immunology</i> , 2018, 9, 329.	2.2	15
942	T Cell Subsets in the Germinal Center: Lessons from the Macaque Model. <i>Frontiers in Immunology</i> , 2018, 9, 348.	2.2	33
943	Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine. <i>Frontiers in Immunology</i> , 2018, 9, 1194.	2.2	34
944	The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. <i>Frontiers in Immunology</i> , 2018, 9, 1397.	2.2	21
945	In Vitro Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4+ T Cells Harboring Reactivated Human Immunodeficiency Virus. <i>Frontiers in Immunology</i> , 2018, 9, 1514.	2.2	22
946	A Bistable Switch in Virus Dynamics Can Explain the Differences in Disease Outcome Following SIV Infections in Rhesus Macaques. <i>Frontiers in Microbiology</i> , 2018, 9, 1216.	1.5	9
947	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326.	0.4	30
948	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243.	6.3	269
949	A new step towards an HIV/AIDS vaccine. <i>Lancet, The</i> , 2018, 392, 192-194.	6.3	9
950	Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying <i>env</i> from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. <i>Journal of Virology</i> , 2018, 92, .	1.5	3
951	Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	1
952	HIV Vaccination: A Roadmap among Advancements and Concerns. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1241.	1.8	34
953	Immune Correlate-Guided HIV Vaccine Design. <i>Cell Host and Microbe</i> , 2018, 24, 25-33.	5.1	44
954	HIV Vaccine Efficacy Trials: RV144 and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 3-30.	0.8	6
955	Monkey Models and HIV Vaccine Research. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 97-124.	0.8	11
956	Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans. <i>Journal of Infectious Diseases</i> , 2018, 218, 1541-1550.	1.9	22
957	Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficiency Virus Type 1 Clade C Envelope Vaccine. <i>Human Gene Therapy</i> , 2018, 29, 1011-1028.	1.4	7
958	Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. <i>Retrovirology</i> , 2018, 15, 24.	0.9	0

#	ARTICLE	IF	CITATIONS
959	SIV-Specific Antibodies are Elicited by a Recombinant Fowlpox Virus Co-expressing SIV Gag and envT. Indian Journal of Microbiology, 2018, 58, 345-352.	1.5	2
960	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. MBio, 2018, 9, .	1.8	82
961	<scp>HIV</scp>/<scp>AIDS</scp> Vaccines: 2018. Clinical Pharmacology and Therapeutics, 2018, 104, 1062-1073.	2.3	32
962	In vitro assessment of biological activity and stability of the ALVAC-HIV vaccine. Vaccine, 2018, 36, 5636-5644.	1.7	2
963	The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. AIDS Research and Human Retroviruses, 2018, 34, 727-738.	0.5	22
964	Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. Retrovirology, 2018, 15, 58.	0.9	32
965	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. Journal of Immunological Methods, 2018, 462, 74-82.	0.6	19
966	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	13.5	173
967	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. Journal of Virology, 2018, 92, .	1.5	39
968	IgA Responses to Microbiota. Immunity, 2018, 49, 211-224.	6.6	240
969	Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6110-6112.	3.3	29
970	Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. Cell Host and Microbe, 2018, 23, 832-844.e6.	5.1	43
971	A step forward for HIV vaccines. Lancet HIV,the, 2018, 5, e338-e339.	2.1	8
972	The Role of Immune Responses in HIV Mother-to-Child Transmission. Advances in Virus Research, 2018, 100, 19-40.	0.9	11
973	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathogens, 2018, 14, e1006987.	2.1	71
974	Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. Journal of Virology, 2018, 92, .	1.5	9
975	Correlates of Protection. , 2018, , 35-40.e4.		22
976	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nature Communications, 2018, 9, 2363.	5.8	46

#	ARTICLE	IF	CITATIONS
977	Human Immunodeficiency Virus Vaccines. , 2018, , 400-429.e25.		0
979	The potential of engineered antibodies for HIV-1 therapy and cure. <i>Current Opinion in Virology</i> , 2019, 38, 70-80.	2.6	34
980	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. <i>Animals</i> , 2019, 9, 526.	1.0	11
981	Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. <i>Vaccines</i> , 2019, 7, 78.	2.1	16
982	Short Communication: Effect of Seminal Plasma on Functions of Monocytes and Granulocytes. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 553-556.	0.5	3
983	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. <i>Vaccines</i> , 2019, 7, 82.	2.1	11
984	Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. <i>Journal of the International AIDS Society</i> , 2019, 22, e25373.	1.2	6
985	Deficient IL-2 Produced by Activated CD56+ T Cells Contributes to Impaired NK Cell-Mediated ADCC Function in Chronic HIV-1 Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1647.	2.2	9
986	HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients. <i>Journal of Infectious Diseases</i> , 2019, 220, 1620-1628.	1.9	10
987	Influenza and Antibody-Dependent Cellular Cytotoxicity. <i>Frontiers in Immunology</i> , 2019, 10, 1457.	2.2	55
988	Nonparametric inference for immune response thresholds of risk in vaccine studies. <i>Annals of Applied Statistics</i> , 2019, 13, 1147-1165.	0.5	4
989	A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. <i>Journal of Immunological Methods</i> , 2019, 473, 112630.	0.6	149
990	Moving the HIV vaccine field forward: concepts of protective immunity. <i>Lancet HIV</i> , the, 2019, 6, e406-e410.	2.1	1
991	Can we just kick-and-kill HIV: possible challenges posed by the epigenetically controlled interplay between HIV and host immunity. <i>Immunotherapy</i> , 2019, 11, 931-935.	1.0	7
992	AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 100-112.	1.8	24
993	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. <i>Cell Reports</i> , 2019, 28, 877-895.e6.	2.9	36
994	Boosting of Markers of Fcγ <sub>3</sub> Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 842-852.	0.5	1
995	Reduced frequency of HIV superinfection in a high-risk cohort in Zambia. <i>Virology</i> , 2019, 535, 11-19.	1.1	1

#	ARTICLE	IF	CITATIONS
996	Novel prime-boost vaccine strategies against HIV-1. <i>Expert Review of Vaccines</i> , 2019, 18, 765-779.	2.0	34
997	Induction of Fc-Mediated Effector Functions Against a Stabilized Inner Domain of HIV-1 gp120 Designed to Selectively Harbor the A32 Epitope Region. <i>Frontiers in Immunology</i> , 2019, 10, 677.	2.2	7
998	HIV vaccine: better to start together?. <i>Lancet HIV</i> , 2019, 6, e724-e725.	2.1	10
999	Fingerprints and paternity testing: a study of genetics and probability in pre-DNA forensic science. <i>Law, Probability and Risk</i> , 2019, 18, 177-199.	1.2	2
1000	Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens. <i>Frontiers in Plant Science</i> , 2019, 10, 1378.	1.7	28
1001	Potential of recombinant <i>Mycobacterium paragordoniae</i> expressing HIV-1 Gag as a prime vaccine for HIV-1 infection. <i>Scientific Reports</i> , 2019, 9, 15515.	1.6	8
1002	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. <i>Journal of Infectious Diseases</i> , 2019, 219, 1755-1765.	1.9	7
1003	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	26
1004	Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission. <i>Current Immunology Reviews</i> , 2019, 15, 102-122.	1.2	24
1005	A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1850.	2.2	21
1006	Plasma Membrane-Associated Restriction Factors and Their Counteraction by HIV-1 Accessory Proteins. <i>Cells</i> , 2019, 8, 1020.	1.8	24
1007	Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. <i>Vaccines</i> , 2019, 7, 103.	2.1	15
1008	Production of <i>E. coli</i> -expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	2
1009	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	46
1010	Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function. <i>Frontiers in Immunology</i> , 2019, 10, 697.	2.2	55
1011	A Sample-Sparing Multiplexed ADCP Assay. <i>Frontiers in Immunology</i> , 2019, 10, 1851.	2.2	42
1012	Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. <i>Vaccines</i> , 2019, 7, 119.	2.1	5
1013	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e737-e749.	2.1	43



#	ARTICLE	IF	CITATIONS
1014	The use of multiplexing technology in the immunodiagnosis of infectious agents. <i>Journal of Immunoassay and Immunochemistry</i> , 2019, 40, 109-122.	0.5	8
1015	Structural Basis for Epitopes in the gp120 Cluster A Region that Invokes Potent Effector Cell Activity. <i>Viruses</i> , 2019, 11, 69.	1.5	20
1016	OMIP-052: An 18-Color Panel for Measuring Th1, Th2, Th17, and Tfh Responses in Rhesus Macaques. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 261-263.	1.1	17
1017	Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants. <i>Journal of Virology</i> , 2019, 93, .	1.5	24
1018	Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC. <i>Journal of Leukocyte Biology</i> , 2019, 105, 551-563.	1.5	12
1019	Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. <i>Molecular Therapy</i> , 2019, 27, 650-660.	3.7	42
1020	Peste des Petits Ruminants Virus Fusion and Hemagglutinin Proteins Trigger Antibody-Dependent Cell-Mediated Cytotoxicity in Infected Cells. <i>Frontiers in Immunology</i> , 2018, 9, 3172.	2.2	9
1021	Maximum diversity weighting for biomarkers with application in HIV vaccine studies. <i>Statistics in Medicine</i> , 2019, 38, 3936-3946.	0.8	1
1022	Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	1.5	7
1023	Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	7
1024	Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine. <i>Journal of Translational Medicine</i> , 2019, 17, 175.	1.8	5
1025	Monkeying Around: Using Non-human Primate Models to Study NK Cell Biology in HIV Infections. <i>Frontiers in Immunology</i> , 2019, 10, 1124.	2.2	21
1027	HIV-1 Envelope FRETted Over by Antibodies. <i>Cell Host and Microbe</i> , 2019, 25, 767-768.	5.1	3
1028	Quantifying Anti-HIV Envelope-Specific Antibodies in Plasma from HIV Infected Individuals. <i>Viruses</i> , 2019, 11, 487.	1.5	10
1029	Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. <i>Journal of Virology</i> , 2019, 93, .	1.5	15
1030	Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. <i>Cell</i> , 2019, 177, 1153-1171.e28.	13.5	293
1031	Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses. <i>PLoS ONE</i> , 2019, 14, e0216949.	1.1	12
1032	Immune Correlates of Disease Progression in Linked HIV-1 Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1062.	2.2	14

#	ARTICLE	IF	CITATIONS
1033	Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells. <i>Biotechnology and Bioengineering</i> , 2019, 116, 2130-2145.	1.7	20
1034	Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. <i>Journal of Virology</i> , 2019, 93, .	1.5	9
1035	Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques. <i>Scientific Reports</i> , 2019, 9, 5661.	1.6	14
1036	Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. <i>Cells</i> , 2019, 8, 365.	1.8	6
1037	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 1025.	2.2	37
1038	Harnessing donor unrestricted T-cells for new vaccines against tuberculosis. <i>Vaccine</i> , 2019, 37, 3022-3030.	1.7	59
1039	Antibody-Induced Internalization of HIV-1 Env Proteins Limits Surface Expression of the Closed Conformation of Env. <i>Journal of Virology</i> , 2019, 93, .	1.5	32
1040	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
1041	The Antibodiomeâ€”Mapping the Humoral Immune Response to HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 169-179.	1.1	13
1042	Phagocytosis of a Model Human Immunodeficiency Virus Target by Human Breast Milk Leukocytes Is Predominantly Granulocyte-Driven When Elicited by Specific Antibody. <i>Breastfeeding Medicine</i> , 2019, 14, 185-192.	0.8	2
1043	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. <i>Journal of Virology</i> , 2019, 93, .	1.5	37
1044	Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
1045	Primary Human Neutrophils Exhibit a Unique HIV-Directed Antibody-Dependent Phagocytosis Profile. <i>Journal of Innate Immunity</i> , 2019, 11, 181-190.	1.8	12
1046	Glycosylation of the HIV-1 Env V1V2 loop to form a native-like structure may not be essential with a nanoparticle vaccine. <i>Future Virology</i> , 2019, 14, 51-54.	0.9	2
1047	Mutually assured destruction: the cold war between viruses and natural killer cells. <i>Current Opinion in Virology</i> , 2019, 34, 130-139.	2.6	20
1048	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019, 50, 677-691.e13.	6.6	77
1049	Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 332.	2.2	156
1050	Lessons for general vaccinology research from attempts to develop an HIV vaccine. <i>Vaccine</i> , 2019, 37, 3400-3408.	1.7	13

#	ARTICLE	IF	CITATIONS
1051	Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. <i>Frontiers in Immunology</i> , 2019, 10, 548.	2.2	194
1052	Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. <i>Frontiers in Immunology</i> , 2019, 10, 717.	2.2	7
1053	Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 91.	1.8	10
1054	Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. <i>Viruses</i> , 2019, 11, 159.	1.5	13
1055	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019, 10, 863.	5.8	27
1056	Semen IgM, IgG1, and IgG3 Differentially Associate With Pro-Inflammatory Cytokines in HIV-Infected Men. <i>Frontiers in Immunology</i> , 2019, 9, 3141.	2.2	5
1057	Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses. <i>Viruses</i> , 2019, 11, 136.	1.5	6
1058	HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. <i>Nature Communications</i> , 2019, 10, 798.	5.8	61
1059	Identification of HIV gp41-specific antibodies that mediate killing of infected cells. <i>PLoS Pathogens</i> , 2019, 15, e1007572.	2.1	35
1060	Glycosylation of HIV Env Impacts IgG Subtype Responses to Vaccination. <i>Viruses</i> , 2019, 11, 153.	1.5	15
1061	Improvement of antibody functionality by structure-guided paratope engraftment. <i>Nature Communications</i> , 2019, 10, 721.	5.8	27
1062	Differential Effect of Mucosal NKp44+Innate Lymphoid Cells and $\gamma\delta$ T Cells on Simian Immunodeficiency Virus Infection Outcome in Rhesus Macaques. <i>Journal of Immunology</i> , 2019, 203, 2459-2471.	0.4	10
1063	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects. <i>MBio</i> , 2019, 10, .	1.8	17
1064	Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. <i>Journal of Virology</i> , 2019, 93, .	1.5	12
1065	Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R $\alpha$ Transcriptional Signature Express Fc $\gamma$ RIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Immunology</i> , 2019, 203, 2210-2221.	0.4	23
1066	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. <i>Frontiers in Immunology</i> , 2019, 10, 2875.	2.2	20
1067	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
1068	Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector. <i>Scientific Reports</i> , 2019, 9, 20005.	1.6	10

#	ARTICLE	IF	CITATIONS
1069	An Inflammatory Story: Antibodies in Tuberculosis Comorbidities. <i>Frontiers in Immunology</i> , 2019, 10, 2846.	2.2	17
1070	Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization. <i>Frontiers in Immunology</i> , 2019, 10, 2968.	2.2	44
1071	An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design. <i>Vaccines</i> , 2019, 7, 208.	2.1	5
1072	Antibody-dependent cellular cytotoxicity targeting CD4-inducible epitopes predicts mortality in HIV-infected infants. <i>EBioMedicine</i> , 2019, 47, 257-268.	2.7	12
1073	Mucosal Antibodies: Defending Epithelial Barriers against HIV-1 Invasion. <i>Vaccines</i> , 2019, 7, 194.	2.1	26
1074	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	2.2	25
1075	Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population. <i>JAMA Network Open</i> , 2019, 2, e1916526.	2.8	77
1076	HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design. , 2019, , .		6
1077	Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 309-317.	1.5	25
1078	Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 253-264.	1.5	10
1079	Fc $\gamma$ 3RIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV. <i>BMC Infectious Diseases</i> , 2019, 19, 1053.	1.3	7
1080	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. <i>PLoS ONE</i> , 2019, 14, e0225622.	1.1	20
1081	Neutralizing antibodies for HIV-1 prevention. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 318-324.	1.5	34
1082	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. <i>PLoS Pathogens</i> , 2019, 15, e1008121.	2.1	19
1083	Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 220-224.	0.9	3
1084	The FCGR2C allele that modulated the risk of HIV-1 infection in the Thai RV144 vaccine trial is implicated in HIV-1 disease progression. <i>Genes and Immunity</i> , 2019, 20, 651-659.	2.2	6
1085	Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 16, 206-216.	1.7	22
1086	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	6.6	153

#	ARTICLE	IF	CITATIONS
1087	Sex differences in vaccine-induced humoral immunity. <i>Seminars in Immunopathology</i> , 2019, 41, 239-249.	2.8	284
1088	Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2019, 93, .	1.5	18
1089	Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time. <i>Journal of Virology</i> , 2019, 93, .	1.5	18
1090	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	1.5	25
1091	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2019, 93, .	1.5	44
1092	Current approaches toward identifying a correlate of immune protection from tuberculosis. <i>Expert Review of Vaccines</i> , 2019, 18, 43-59.	2.0	18
1093	The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 46-51.	1.0	5
1094	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
1095	Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon. <i>Virology</i> , 2019, 529, 57-64.	1.1	12
1096	Harnessing Antibody-Dependent Cellular Cytotoxicity To Control HIV-1 Infection. <i>ACS Infectious Diseases</i> , 2019, 5, 158-176.	1.8	5
1097	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. <i>Statistical Methods in Medical Research</i> , 2020, 29, 78-93.	0.7	1
1098	Novel Approaches for Development of Human Immunodeficiency Virus Preexposure Prophylaxis Agents. <i>Journal of Infectious Diseases</i> , 2020, 221, 172-174.	1.9	1
1099	Maternal Envelope gp41 Ectodomain-Specific Antibodies Are Associated With Increased Mother-to-Child Transmission of Human Immunodeficiency Virus-1. <i>Journal of Infectious Diseases</i> , 2020, 221, 232-237.	1.9	7
1100	Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains. <i>Journal of Infectious Diseases</i> , 2020, 221, 756-765.	1.9	2
1101	T cell-based strategies for HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 713-722.	1.4	39
1102	Complement in malaria immunity and vaccines. <i>Immunological Reviews</i> , 2020, 293, 38-56.	2.8	36
1103	The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. <i>Immunology and Cell Biology</i> , 2020, 98, 253-263.	1.0	42
1104	HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use. <i>Lancet HIV</i> , 2020, 7, e141-e148.	2.1	2

#	ARTICLE	IF	CITATIONS
1105	Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 371-378.	1.3	8
1106	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	2.9	15
1107	Mucosal Vaccines Against HIV/SIV Infection. , 2020, , 713-722.		0
1108	Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine. <i>Aids</i> , 2020, 34, 25-32.	1.0	9
1109	Serum IgA Fc effector functions in infectious disease and cancer. <i>Immunology and Cell Biology</i> , 2020, 98, 276-286.	1.0	44
1110	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet, The</i> , 2020, 395, 384-388.	6.3	44
1111	Dendritic Cells in HIV/SIV Prophylactic and Therapeutic Vaccination. <i>Viruses</i> , 2020, 12, 24.	1.5	11
1112	Recent insights into Fc-mediated effector responses to HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 282-289.	1.5	11
1113	Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice. <i>Microorganisms</i> , 2020, 8, 1490.	1.6	1
1114	Challenges of Developing Novel Vaccines With Particular Global Health Importance. <i>Frontiers in Immunology</i> , 2020, 11, 517290.	2.2	30
1115	Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo. <i>Immunity</i> , 2020, 53, 548-563.e8.	6.6	149
1116	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25
1117	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , 2020, 7, e688-e698.	2.1	58
1118	Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2033-2041.	1.4	2
1119	Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection. <i>Aids</i> , 2020, 34, 1313-1323.	1.0	12
1120	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 95, .	1.5	5
1121	Understanding protection from SARS-CoV-2 by studying reinfection. <i>Nature Medicine</i> , 2020, 26, 1680-1681.	15.2	44
1122	Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 316-323.	1.5	6

#	ARTICLE	IF	CITATIONS
1123	Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 19, 78-88.	1.8	10
1124	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. <i>Virus Research</i> , 2020, 288, 198141.	1.1	116
1125	Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. <i>Vaccine</i> , 2020, 38, 5814-5821.	1.7	3
1126	Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18002-18009.	3.3	44
1127	Evaluation of HIV-1 neutralizing and binding antibodies in maternal-infant transmission in Thailand. <i>Virology</i> , 2020, 548, 152-159.	1.1	2
1128	Next-generation rotavirus vaccine developers meeting: Summary of a meeting sponsored by PATH and the Bill & Melinda Gates Foundation (19-20 June 2019, Geneva). <i>Vaccine</i> , 2020, 38, 8247-8254.	1.7	8
1129	Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers. <i>Vaccines</i> , 2020, 8, 681.	2.1	5
1130	IL-18 Responsiveness Defines Limitations in Immune Help for Specialized Fcγ3NK Cells. <i>Journal of Immunology</i> , 2020, 205, 3429-3442.	0.4	4
1131	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020, 5, 107.	2.9	11
1132	Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers. <i>Frontiers in Immunology</i> , 2020, 11, 583820.	2.2	8
1133	Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. <i>Frontiers in Immunology</i> , 2020, 11, 590780.	2.2	72
1134	Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1744.	2.2	4
1135	A FcγRIIIa polymorphism has a HLA-B57 and HLA-B27 independent effect on HIV disease outcome. <i>Genes and Immunity</i> , 2020, 21, 263-268.	2.2	5
1136	The role of IgG Fc receptors in antibody-dependent enhancement. <i>Nature Reviews Immunology</i> , 2020, 20, 633-643.	10.6	340
1137	Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women. <i>Frontiers in Immunology</i> , 2020, 11, 1274.	2.2	1
1138	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. <i>MBio</i> , 2020, 11, .	1.8	6
1139	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020, 10, 13031.	1.6	10
1140	Harnessing Natural Killer Cell Innate and Adaptive Traits in HIV Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 395.	1.8	10

#	ARTICLE	IF	CITATIONS
1141	RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines. <i>Scientific Reports</i> , 2020, 10, 14056.	1.6	4
1142	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. <i>PLoS Pathogens</i> , 2020, 16, e1008764.	2.1	37
1143	Higher frequencies of functional HIV-envelope-specific memory B cells are associated with nonprogressive HIV infection in Indian population. <i>Aids</i> , 2020, 34, 1603-1608.	1.0	1
1144	A Zigzag but Upward Way to Develop an HIV-1 Vaccine. <i>Vaccines</i> , 2020, 8, 511.	2.1	5
1145	Natural killer cell phenotype is altered in HIV-exposed seronegative women. <i>PLoS ONE</i> , 2020, 15, e0238347.	1.1	18
1146	Bringing the path toward an HIV-1 vaccine into focus. <i>PLoS Pathogens</i> , 2020, 16, e1008663.	2.1	12
1147	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
1148	Probing the Structure of the HIV-1 Envelope Trimer Using Aspartate Scanning Mutagenesis. <i>Journal of Virology</i> , 2020, 94, .	1.5	4
1149	Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1001-1046.	1.3	7
1150	HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research. <i>Viruses</i> , 2020, 12, 1469.	1.5	3
1151	The V2 loop of HIV gp120 delivers costimulatory signals to CD4 <sup>+</sup> T cells through Integrin $\alpha 4\beta 7$ and promotes cellular activation and infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32566-32573.	3.3	14
1152	Exploring the Engagement of Racial and Ethnic Minorities in HIV Treatment and Vaccine Clinical Trials: A Scoping Review of Literature and Implications for Future Research. <i>AIDS Patient Care and STDs</i> , 2020, 34, 399-416.	1.1	26
1153	Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers. <i>Microorganisms</i> , 2020, 8, 1722.	1.6	7
1154	A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	7
1155	The NF- $\kappa$ B/leukemia inhibitory factor/STAT3 signaling pathway in antibody-mediated suppression of Sindbis virus replication in neurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29035-29045.	3.3	13
1156	Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	37
1157	The search for an HIV vaccine, the journey continues. <i>Journal of the International AIDS Society</i> , 2020, 23, e25506.	1.2	13
1158	Impact of T <sub>H</sub> 1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	30



#	ARTICLE	IF	CITATIONS
1159	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. <i>Frontiers in Immunology</i> , 2020, 11, 984.	2.2	9
1160	An SAMT-247 Microbicide Provides Potent Protection against Intravaginal Simian Immunodeficiency Virus Infection of Rhesus Macaques, whereas an Added Vaccine Component Elicits Mixed Outcomes. <i>Journal of Immunology</i> , 2020, 204, 3315-3328.	0.4	8
1161	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	2.9	43
1162	Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells. <i>Microorganisms</i> , 2020, 8, 710.	1.6	7
1163	Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost. <i>Frontiers in Immunology</i> , 2020, 11, 719.	2.2	8
1164	Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in non-human primates. <i>PLoS ONE</i> , 2020, 15, e0233577.	1.1	9
1165	An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
1166	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. <i>Science Immunology</i> , 2020, 5, .	5.6	90
1167	Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41. <i>Frontiers in Immunology</i> , 2020, 11, 1141.	2.2	23
1168	Innate and Adaptive Anti-SIV Responses in Macaque Semen: Implications for Infectivity and Risk of Transmission. <i>Frontiers in Immunology</i> , 2020, 11, 850.	2.2	7
1169	Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development. <i>Frontiers in Immunology</i> , 2020, 11, 315.	2.2	14
1170	Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity. <i>Vaccine</i> , 2020, 38, 3436-3446.	1.7	5
1171	Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease. <i>Journal of Infectious Diseases</i> , 2020, 221, S45-S59.	1.9	25
1172	Timely development of vaccines against SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2020, 9, 542-544.	3.0	80
1173	Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection. <i>BMC Medicine</i> , 2020, 18, 81.	2.3	45
1174	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. <i>PLoS Pathogens</i> , 2020, 16, e1008377.	2.1	14
1176	A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants. <i>Journal of Immunological Methods</i> , 2020, 480, 112766.	0.6	4
1177	Key Positions of HIV-1 Env and Signatures of Vaccine Efficacy Show Gradual Reduction of Population Founder Effects at the Clade and Regional Levels. <i>MBio</i> , 2020, 11, .	1.8	11

#	ARTICLE	IF	CITATIONS
1178	Mucosal-associated invariant T (MAIT) cells provide B-cell help in vaccinated and subsequently SIV-infected Rhesus Macaques. <i>Scientific Reports</i> , 2020, 10, 10060.	1.6	26
1179	Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. <i>MSphere</i> , 2020, 5, .	1.3	2
1180	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. <i>PLoS Pathogens</i> , 2020, 16, e1008522.	2.1	11
1181	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e238-e248.	2.1	33
1182	Impact of the expression system on the immune responses to self-assembling protein nanoparticles (SAPNs) displaying HIV-1 V1V2 loop. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102255.	1.7	5
1183	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	3.9	27
1184	Natural killer cell activation by respiratory syncytial virus-specific antibodies is decreased in infants with severe respiratory infections and correlates with Fc-glycosylation. <i>Clinical and Translational Immunology</i> , 2020, 9, e1112.	1.7	27
1185	A Systematic Approach to HIV-1 Vaccine Immunogen Selection. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 762-770.	0.5	6
1186	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	1.6	17
1187	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020, 11, 948.	5.8	27
1188	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , 2020, 16, e1007626.	1.5	20
1189	Vaccine boosts: balancing response magnitude and character. <i>Lancet HIV</i> , 2020, 7, e217-e219.	2.1	1
1190	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020, 30, 1553-1569.e6.	2.9	21
1191	Innovations in HIV-1 Vaccine Design. <i>Clinical Therapeutics</i> , 2020, 42, 499-514.	1.1	20
1192	Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B. <i>Vaccines</i> , 2020, 8, 70.	2.1	13
1193	Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination. <i>Vaccine</i> , 2020, 38, 1678-1689.	1.7	2
1194	Modulation of Vaccine-Induced HIV-1-Specific Immune Responses by Co-Electroporation of PD-L1 Encoding DNA. <i>Vaccines</i> , 2020, 8, 27.	2.1	11
1195	Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. <i>Vaccine</i> , 2020, 38, 1953-1961.	1.7	25

#	ARTICLE	IF	CITATIONS
1196	Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice. <i>Vaccine</i> , 2020, 38, 2149-2159.	1.7	3
1197	Higher Baseline ADCC Responses in Chronic Nonprogressive HIV Infection Are Associated with Reduced HIV Burden in Later Course of Disease. <i>Viral Immunology</i> , 2020, 33, 77-85.	0.6	2
1199	Nanoparticle-Based Immunoengineered Approaches for Combating HIV. <i>Frontiers in Immunology</i> , 2020, 11, 789.	2.2	20
1200	Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development. <i>Vaccines</i> , 2020, 8, 194.	2.1	7
1201	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020, 94, .	1.5	19
1202	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	8
1203	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	9.5	74
1204	A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. <i>Vaccines</i> , 2020, 8, 171.	2.1	6
1205	Army Liposome Formulation (ALF) family of vaccine adjuvants. <i>Expert Review of Vaccines</i> , 2020, 19, 279-292.	2.0	59
1206	A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities. <i>Journal of Virology</i> , 2020, 94, .	1.5	4
1207	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , 2020, 5, .	1.3	3
1208	Glycosylation as a tool for rational vaccine design. <i>Biotechnology and Bioengineering</i> , 2020, 117, 2556-2570.	1.7	15
1209	Characterization and Immunogenicity of HIV Envelope gp140 Zera <sup>®</sup> Tagged Antigens. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 321.	2.0	4
1210	Methods for Feature Selection in Down-Selection of Vaccine Regimens Based on Multivariate Immune Response Endpoints. <i>Statistics in Biosciences</i> , 2020, 12, 353-375.	0.6	1
1211	HIV/AIDS Research for the Future. <i>Cell Host and Microbe</i> , 2020, 27, 499-501.	5.1	6
1212	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. <i>Cell Host and Microbe</i> , 2020, 27, 963-975.e5.	5.1	23
1213	Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. <i>Nature Nanotechnology</i> , 2021, 16, 1-14.	15.6	150
1214	Current advances in the development of SARS-CoV-2 vaccines. <i>International Journal of Biological Sciences</i> , 2021, 17, 8-19.	2.6	114

#	ARTICLE	IF	CITATIONS
1215	Self-amplifying RNA vaccines for infectious diseases. <i>Gene Therapy</i> , 2021, 28, 117-129.	2.3	212
1216	CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts. <i>Journal of Virology</i> , 2021, 95, .	1.5	3
1217	When Therapeutic IgA Antibodies Might Come of Age. <i>Pharmacology</i> , 2021, 106, 9-19.	0.9	36
1218	Evaluating the surrogacy of multiple vaccine-induced immune response biomarkers in HIV vaccine trials. <i>Biostatistics</i> , 2021, 22, 421-436.	0.9	0
1219	HIV-1 Entry and Prospects for Protecting against Infection. <i>Microorganisms</i> , 2021, 9, 228.	1.6	5
1220	Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies. <i>ELife</i> , 2021, 10, .	2.8	3
1221	The Role of Vaccines in Combating Antimicrobial Resistance. <i>Sustainable Agriculture Reviews</i> , 2021, , 347-430.	0.6	3
1222	HIV vaccinology: 2021 update. <i>Seminars in Immunology</i> , 2021, 51, 101470.	2.7	31
1223	Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. <i>Npj Vaccines</i> , 2021, 6, 15.	2.9	5
1224	DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 833-841.	3.0	6
1226	HIV/AIDS Global Epidemic. , 2021, , 1-30.		0
1227	RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial. <i>Vaccine</i> , 2021, 39, 687-698.	1.7	9
1228	HIV-1 Envelope Glycosylation and the Signal Peptide. <i>Vaccines</i> , 2021, 9, 176.	2.1	5
1229	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. <i>Journal of Immunology</i> , 2021, 206, 1266-1283.	0.4	8
1230	Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. <i>Journal of Infectious Diseases</i> , 2021, 223, S22-S31.	1.9	7
1231	HIV mRNA Vaccines—Progress and Future Paths. <i>Vaccines</i> , 2021, 9, 134.	2.1	45
1232	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. <i>IScience</i> , 2021, 24, 102047.	1.9	16
1233	Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells. <i>Nano Today</i> , 2021, 36, 101056.	6.2	7

#	ARTICLE	IF	CITATIONS
1234	Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases. <i>Vaccines</i> , 2021, 9, 112.	2.1	5
1235	Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates. <i>Frontiers in Immunology</i> , 2021, 12, 623996.	2.2	10
1236	The Immunological Impact of Adenovirus Early Genes on Vaccine-Induced Responses in Mice and Nonhuman Primates. <i>Journal of Virology</i> , 2021, 95, .	1.5	1
1237	Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques. <i>Npj Vaccines</i> , 2021, 6, 34.	2.9	7
1238	Production of HIV-1 Env-Specific Antibodies Mediating Innate Immune Functions Depends on Cognate Interleukin-21- Secreting CD4 <sup>+</sup> T Cells. <i>Journal of Virology</i> , 2021, 95, .	1.5	4
1239	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120 <sup>MF59</sup> in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	13.9	144
1240	Preparation of a New Nanobody and Its Usage in Treatment of Spontaneous Hypertension. <i>Science of Advanced Materials</i> , 2021, 13, 497-508.	0.1	0
1241	The Importance of Regulation in Natural Immunity to HIV. <i>Vaccines</i> , 2021, 9, 271.	2.1	2
1242	Adjuvant <sup>em</sup> -mediated enhancement of the immune response to HIV vaccines. <i>FEBS Journal</i> , 2022, 289, 3317-3334.	2.2	10
1243	Innate immune signatures to a partially-eficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	2.1	19
1244	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	2.9	46
1245	Immunization by exposure to live virus (SIV <sup>mne</sup> /HIV-2287) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge. <i>PLoS ONE</i> , 2021, 16, e0240495.	1.1	0
1246	B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 564-578.e9.	5.1	18
1247	The diversity of HIV-1 fights against vaccine efficacy: how self-assembling protein nanoparticle technology may fight back. <i>Nanomedicine</i> , 2021, 16, 673-680.	1.7	0
1248	Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir. <i>Frontiers in Immunology</i> , 2021, 12, 663919.	2.2	5
1250	Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers. <i>PLoS Pathogens</i> , 2021, 17, e1009478.	2.1	5
1251	Improved HIV-positive infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts. <i>Cell Reports Medicine</i> , 2021, 2, 100254.	3.3	16
1252	Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China. <i>BMC Infectious Diseases</i> , 2021, 21, 341.	1.3	6

#	ARTICLE	IF	CITATIONS
1253	Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State. <i>MBio</i> , 2021, 12, .	1.8	10
1254	Targeting Fc effector function in vaccine design. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 467-477.	1.5	17
1255	Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice. <i>Journal of Virology</i> , 2021, 95, .	1.5	6
1256	High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. <i>Cell</i> , 2021, 184, 2927-2938.e11.	13.5	35
1259	Are Fc Gamma Receptor Polymorphisms Important in HIV-1 Infection Outcomes and Latent Reservoir Size?. <i>Frontiers in Immunology</i> , 2021, 12, 656894.	2.2	1
1260	The path to find an HIV vaccine. <i>Journal of the International AIDS Society</i> , 2021, 24, e25749.	1.2	6
1261	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 678511.	2.2	11
1262	Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 625030.	2.2	6
1263	Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design. <i>Viruses</i> , 2021, 13, 884.	1.5	1
1264	Oral Vaccination Approaches for Anti-SHIV Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 702705.	2.2	2
1265	Four-parameter paired response curve for serial dilution assays. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, 1-16.	0.4	0
1266	A diverse collection of B cells responded to HIV infection in infant BG505. <i>Cell Reports Medicine</i> , 2021, 2, 100314.	3.3	6
1267	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
1268	Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein. <i>AIDS Research and Human Retroviruses</i> , 2021, , .	0.5	0
1271	PET/CT targeted tissue sampling reveals virus specific dIgA can alter the distribution and localization of HIV after rectal exposure. <i>PLoS Pathogens</i> , 2021, 17, e1009632.	2.1	11
1272	The current and future role of nanovaccines in HIV-1 vaccine development. <i>Expert Review of Vaccines</i> , 2021, 20, 935-944.	2.0	8
1273	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. <i>Vaccine</i> , 2021, 39, 3879-3891.	1.7	3
1274	Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2021, 95, e0021921.	1.5	7

#	ARTICLE	IF	CITATIONS
1275	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021, 7, veab057.	2.2	2
1277	The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. <i>Virology</i> , 2021, 559, 1-9.	1.1	29
1278	Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. <i>Vaccines</i> , 2021, 9, 750.	2.1	11
1279	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. <i>Vaccine</i> , 2021, 39, 4641-4650.	1.7	1
1280	Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1. <i>Journal of Virology</i> , 2021, 95, e0236820.	1.5	12
1281	Differential expression of HIV envelope epitopes on the surface of HIV-Infected macrophages and CD4+ T cells. <i>Antiviral Research</i> , 2021, 191, 105085.	1.9	3
1282	Elevated HIV Infection of CD4 T Cells in MRKAd5 Vaccine Recipients Due to CD8 T Cells Targeting Adapted Epitopes. <i>Journal of Virology</i> , 2021, 95, e0016021.	1.5	4
1283	A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. <i>Lancet HIV</i> , 2021, 8, e449-e452.	2.1	11
1285	Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG. <i>Retrovirology</i> , 2021, 18, 23.	0.9	3
1286	Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions. <i>Vaccines</i> , 2021, 9, 975.	2.1	5
1287	Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges. <i>Frontiers in Immunology</i> , 2021, 12, 705592.	2.2	3
1288	Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection. <i>Npj Vaccines</i> , 2021, 6, 110.	2.9	11
1289	Targeting natural killer cells to enhance vaccine responses. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 789-801.	4.0	29
1290	Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection. <i>Journal of Virology</i> , 2021, 95, e0162521.	1.5	1
1291	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. <i>ELife</i> , 2021, 10, .	2.8	12
1292	Identification of a CD4-binding site-directed antibody with ADCC activity from a chronic HIV-1-infected Chinese donor. <i>Virus Research</i> , 2021, 302, 198470.	1.1	3
1293	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021, 22, 1294-1305.	7.0	20
1294	Hidden in plain sight: uncovering the role of CREB1 in HIV-1 vaccine-induced immunity. <i>Nature Immunology</i> , 2021, 22, 1199-1200.	7.0	1

#	ARTICLE	IF	CITATIONS
1295	Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis. <i>Frontiers in Immunology</i> , 2021, 12, 734304.	2.2	9
1296	HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. <i>Frontiers in Immunology</i> , 2021, 12, 733958.	2.2	14
1298	A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100386.	3.3	8
1299	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. <i>Nature Medicine</i> , 2021, 27, 2012-2024.	15.2	206
1300	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	44
1301	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. <i>Vaccines</i> , 2021, 9, 1001.	2.1	2
1303	A government-led effort to identify correlates of protection for COVID-19 vaccines. <i>Nature Medicine</i> , 2021, 27, 1493-1494.	15.2	26
1304	Current Status of HIV-1 Vaccines. <i>Vaccines</i> , 2021, 9, 1026.	2.1	17
1305	TFH Cells Induced by Vaccination and Following SIV Challenge Support Env-Specific Humoral Immunity in the Rectal-Genital Tract and Circulation of Female Rhesus Macaques. <i>Frontiers in Immunology</i> , 2020, 11, 608003.	2.2	2
1306	Polyfunctional Tier 2 Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. <i>Journal of Immunology</i> , 2021, 206, 999-1012.	0.4	5
1307	Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection. <i>Cell Host and Microbe</i> , 2021, 29, 13-22.	5.1	24
1308	Electroporation-Mediated Administration of Candidate DNA Vaccines Against HIV-1. <i>Methods in Molecular Biology</i> , 2014, 1121, 291-307.	0.4	7
1309	Immune System Modulation by Helminth Infections: Potential Impact on HIV Transmission and Disease Progression. <i>Advances in Experimental Medicine and Biology</i> , 2014, 828, 131-149.	0.8	1
1310	Cocaine and HIV Infection. , 2016, , 75-103.		2
1311	Development of Vaccines Using SeV Vectors Against AIDS and Other Infectious Diseases. , 2013, , 127-149.		1
1313	The Conformational States of the HIV-1 Envelope Glycoproteins. <i>Trends in Microbiology</i> , 2020, 28, 655-667.	3.5	66
1314	Quantitative analyses reveal distinct sensitivities of the capture of HIV-1 primary viruses and pseudoviruses to broadly neutralizing antibodies. <i>Virology</i> , 2017, 508, 188-198.	1.1	7
1315	Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by $\alpha 4 \beta 7$ integrin. <i>Virology</i> , 2017, 508, 199-212.	1.1	18



#	ARTICLE	IF	CITATIONS
1316	Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans. <i>Cell Reports Medicine</i> , 2020, 1, 100015.	3.3	10
1317	Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help. <i>Nature Communications</i> , 2020, 11, 2550.	5.8	17
1318	Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques. <i>Scientific Reports</i> , 2020, 10, 22077.	1.6	7
1319	Modulation of innate and adaptive cellular immunity relevant to HIV-1 vaccine design by seminal plasma. <i>Aids</i> , 2017, 31, 333-342.	1.0	13
1320	DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. <i>Journal of General Virology</i> , 2017, 98, 2143-2155.	1.3	9
1321	Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. <i>Journal of General Virology</i> , 2015, 96, 1478-1483.	1.3	10
1330	Antibodies Targeting the Envelope of HIV-1. , 0, , 191-208.		1
1331	Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection. <i>MSphere</i> , 2020, 5, .	1.3	7
1332	Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. <i>JCI Insight</i> , 2019, 4, .	2.3	50
1333	A composite immune signature parallels disease progression across T1D subjects. <i>JCI Insight</i> , 2019, 4, .	2.3	15
1334	HIV vaccine delayed boosting increases Env variable region 2â€™specific antibody effector functions. <i>JCI Insight</i> , 2020, 5, .	2.3	18
1335	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. <i>JCI Insight</i> , 2020, 5, .	2.3	12
1336	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , 2020, 5, .	2.3	25
1337	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. <i>JCI Insight</i> , 2020, 5, .	2.3	12
1338	Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. <i>JCI Insight</i> , 2017, 2, e88226.	2.3	14
1339	Tissue memory B cell repertoire analysis after ALVAC/AIDS VAX B/E gp120 immunization of rhesus macaques. <i>JCI Insight</i> , 2016, 1, e88522.	2.3	10
1340	Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. <i>JCI Insight</i> , 2018, 3, .	2.3	16
1341	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. <i>Journal of Clinical Investigation</i> , 2019, 129, 1314-1328.	3.9	28

#	ARTICLE	IF	CITATIONS
1342	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	3.9	95
1343	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. <i>Journal of Clinical Investigation</i> , 2019, 129, 4769-4785.	3.9	27
1344	Simplified steps to heterologous prime-boost HIV vaccine development?. <i>Journal of Clinical Investigation</i> , 2019, 129, 4572-4573.	3.9	1
1345	Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. <i>Journal of Clinical Investigation</i> , 2013, 123, 2183-2192.	3.9	310
1346	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	3.9	99
1347	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 4843-4856.	3.9	25
1348	Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2016, 126, 415-423.	3.9	64
1349	Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. <i>Journal of Clinical Investigation</i> , 2015, 125, 2702-2706.	3.9	68
1351	Harnessing the protective potential of HIV-1 neutralizing antibodies. <i>F1000Research</i> , 2016, 5, 20.	0.8	4
1352	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	3.9	8
1353	A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity. <i>PLoS ONE</i> , 2012, 7, e42163.	1.1	11
1354	HIV-1 Envelope Resistance to Proteasomal Cleavage: Implications for Vaccine Induced Immune Responses. <i>PLoS ONE</i> , 2012, 7, e42579.	1.1	13
1355	Neutralization of Tier-2 Viruses and Epitope Profiling of Plasma Antibodies from Human Immunodeficiency Virus Type 1 Infected Donors from India. <i>PLoS ONE</i> , 2012, 7, e43704.	1.1	10
1356	Serum Neutralizing Activities from a Beijing Homosexual Male Cohort Infected with Different Subtypes of HIV-1 in China. <i>PLoS ONE</i> , 2012, 7, e47548.	1.1	2
1357	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. <i>PLoS ONE</i> , 2012, 7, e48781.	1.1	56
1358	Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design. <i>PLoS ONE</i> , 2013, 8, e64405.	1.1	53
1359	Shaping T Cell - B Cell Collaboration in the Response to Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 by Peptide Priming. <i>PLoS ONE</i> , 2013, 8, e65748.	1.1	6
1360	An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells. <i>PLoS ONE</i> , 2013, 8, e67309.	1.1	4

#	ARTICLE	IF	CITATIONS
1361	HIV-1 Envelope Glycoprotein Variable Loops Are Indispensable for Envelope Structural Integrity and Virus Entry. PLoS ONE, 2013, 8, e69789.	1.1	22
1362	Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2. PLoS ONE, 2013, 8, e70859.	1.1	48
1363	Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice. PLoS ONE, 2013, 8, e71601.	1.1	16
1364	Copy Number Variation of Fc Gamma Receptor Genes in HIV-Infected and HIV-Tuberculosis Co-Infected Individuals in Sub-Saharan Africa. PLoS ONE, 2013, 8, e78165.	1.1	18
1365	Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C. PLoS ONE, 2013, 8, e82380.	1.1	25
1366	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. PLoS ONE, 2014, 9, e87572.	1.1	248
1367	Computational Prediction of Neutralization Epitopes Targeted by Human Anti-V3 HIV Monoclonal Antibodies. PLoS ONE, 2014, 9, e89987.	1.1	8
1368	Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies. PLoS ONE, 2014, 9, e97229.	1.1	59
1369	CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants. PLoS ONE, 2014, 9, e111334.	1.1	9
1370	Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA. PLoS ONE, 2014, 9, e113463.	1.1	40
1371	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. PLoS ONE, 2014, 9, e114709.	1.1	11
1372	Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E. PLoS ONE, 2015, 10, e0115582.	1.1	10
1373	Potent Functional Antibody Responses Elicited by HIV-1 DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults. PLoS ONE, 2015, 10, e0118486.	1.1	42
1374	Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial. PLoS ONE, 2015, 10, e0119629.	1.1	43
1375	Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. PLoS ONE, 2015, 10, e0128823.	1.1	9
1376	HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. PLoS ONE, 2015, 10, e0131748.	1.1	37
1377	A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen. PLoS ONE, 2015, 10, e0133595.	1.1	8
1378	A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV. PLoS ONE, 2015, 10, e0136862.	1.1	17

#	ARTICLE	IF	CITATIONS
1379	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. PLoS ONE, 2015, 10, e0141456.	1.1	24
1380	Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to $\alpha 4\beta 7$ Integrin Receptor. PLoS ONE, 2015, 10, e0143895.	1.1	41
1381	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS ONE, 2016, 11, e0153484.	1.1	20
1382	Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission. PLoS ONE, 2016, 11, e0154656.	1.1	23
1383	Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. PLoS ONE, 2016, 11, e0157391.	1.1	33
1384	HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS ONE, 2016, 11, e0160341.	1.1	7
1385	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS ONE, 2016, 11, e0161753.	1.1	16
1386	Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic $\alpha$ -Helical Structure. PLoS ONE, 2017, 12, e0170530.	1.1	13
1387	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS ONE, 2017, 12, e0179597.	1.1	29
1388	Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. PLoS ONE, 2017, 12, e0180245.	1.1	20
1389	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS ONE, 2017, 12, e0180720.	1.1	55
1390	Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes. PLoS ONE, 2018, 13, e0190869.	1.1	1
1391	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. PLoS ONE, 2020, 15, e0226803.	1.1	16
1392	Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. PLoS Pathogens, 2015, 11, e1005101.	2.1	59
1393	Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. PLoS Pathogens, 2016, 12, e1005431.	2.1	18
1394	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathogens, 2016, 12, e1005742.	2.1	81
1395	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	2.1	38
1396	Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques. PLoS Pathogens, 2017, 13, e1006529.	2.1	19

#	ARTICLE	IF	CITATIONS
1397	eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients. <i>PLoS Pathogens</i> , 2017, 13, e1006786.	2.1	24
1398	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , 2018, 14, e1006888.	2.1	26
1399	Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence. <i>PLoS Pathogens</i> , 2020, 16, e1008983.	2.1	3
1400	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020, 16, e1009101.	2.1	13
1401	Sex Differences in HIV Infection: Mystique Versus Machismo. <i>Pathogens and Immunity</i> , 2018, 3, 82.	1.4	10
1402	Lessons Learned from HIV Vaccine Clinical Efficacy Trials. <i>Current HIV Research</i> , 2014, 11, 441-449.	0.2	38
1403	Social Justice and HIV Vaccine Research in the Age of Pre-Exposure Prophylaxis and Treatment as Prevention. <i>Current HIV Research</i> , 2014, 11, 473-480.	0.2	9
1404	Opportunities to Exploit Non-Neutralizing HIV-Specific Antibody Activity. <i>Current HIV Research</i> , 2013, 11, 365-377.	0.2	37
1405	Fc Receptor-Mediated Immune Responses: New Tools But Increased Complexity in HIV Prevention. <i>Current HIV Research</i> , 2013, 11, 407-420.	0.2	28
1406	HIV-1 Variable Loop 2 and its Importance in HIV-1 Infection and Vaccine Development. <i>Current HIV Research</i> , 2013, 11, 427-438.	0.2	25
1407	Protein-Based HIV-1 Microbicides. <i>Current HIV Research</i> , 2014, 11, 576-594.	0.2	9
1408	HIV-1/SIV Humoral Responses in External Secretions. <i>Current Immunology Reviews</i> , 2019, 15, 49-62.	1.2	2
1409	Fcgbp – A Potential Viral Trap in RV144. <i>Open AIDS Journal</i> , 2014, 8, 21-24.	0.1	23
1411	Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection. <i>Viruses</i> , 2020, 12, 75.	1.5	19
1412	Genomic-Regulation of Active Retroviral Elements as a Model for HIV Cure. <i>Journal of Antivirals &amp; Antiretrovirals</i> , 2015, 07, .	0.1	2
1413	Challenges on Induction of Broadly Neutralizing Antibodies for Optimization of HIV Vaccines Development and Vectored Immunoprophylaxis. <i>Journal of Immune Based Therapies, Vaccines and Antimicrobials</i> , 2013, 02, 9-13.	0.2	2
1414	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. <i>ELife</i> , 2019, 8, .	2.8	6
1415	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39

#	ARTICLE	IF	CITATIONS
1417	NK cell-based therapies for HIV infection: Investigating current advances and future possibilities. Journal of Leukocyte Biology, 2021, , .	1.5	4
1418	A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques. Npj Vaccines, 2021, 6, 123.	2.9	2
1419	Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Human Vaccines and Immunotherapeutics, 2021, 17, 4328-4344.	1.4	13
1421	Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity. Cell Reports Medicine, 2021, 2, 100412.	3.3	15
1422	HIV-1 protection: Antibodies move in for the kill. Cell Reports Medicine, 2021, 2, 100428.	3.3	1
1423	Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature, 2021, 600, 701-706.	13.7	180
1424	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. Human Immunology, 2022, 83, 53-60.	1.2	3
1427	HIV-specific ADCC: preventive and therapeutic vaccine potential. Microbiology Australia, 2014, 35, 105.	0.1	0
1428	Preventing HIV-1 Transmission Through Vaccine-Induced Immune Responses. , 2014, , 1-10.		0
1429	Non-neutralizing Antibody Responses and Protection Against HIV-1. , 2014, , 1-6.		0
1430	Vaccines & Vaccine Technologies. , 0, , .		1
1431	Inhibition of HIV-1 Spread: Cell-Free Versus Cell-Cell. , 2014, , 1-13.		0
1432	Natural Killer Cells and their Role in Preventing HIV-1 Transmission. , 2014, , 1-10.		0
1433	Vaccines for Human Immunodeficiency Virus Type 1 Infection. , 2015, , 1666-1673.e4.		1
1434	Vector-Mediated In Vivo Antibody Expression. , 0, , 427-440.		0
1435	Inhibition of HIV-1 Spread: Cell-Free Versus Cell-Cell. , 2016, , 1-13.		0
1437	Efficacy Trials and Progress of HIV Vaccines. Journal of Cell Science & Therapy, 2017, 08, .	0.3	0
1438	Effects of Delay and Drug on HIV Infection. Advances in Intelligent Systems and Computing, 2017, , 376-391.	0.5	0

#	ARTICLE	IF	CITATIONS
1441	Clues to finding correlates of risk/protection for HIV-1 vaccines. F1000Research, 0, 6, 868.	0.8	0
1442	Non-neutralizing Antibody Responses and Protection Against HIV-1. , 2018, , 1539-1544.		0
1443	SIVmac Infection of Macaques, Immunopathogenesis of. , 2018, , 1896-1908.		0
1444	Natural Killer Cells and Their Role in Preventing HIV-1 Transmission. , 2018, , 1433-1441.		0
1445	Inhibition of HIV-1 Spread: Cell-Free Versus Cell-Cell. , 2018, , 1114-1125.		0
1446	Identifying Opportunities to Block HIV-1 Transmission in the Female Genital Tract. , 2018, , 1048-1056.		0
1447	Role of Antibodies in HIV Transmission. , 2018, , 1810-1818.		0
1448	Preventing HIV-1 Transmission Through Vaccine-Induced Immune Responses. , 2018, , 1690-1698.		0
1453	Analysis of T-Cell Immune Responses as Measured by Intracellular Cytokine Staining with Application to Vaccine Clinical Trials. Springer Proceedings in Mathematics and Statistics, 2019, , 249-262.	0.1	0
1454	Pediatric HIV-1 Acquisition and Lifelong Consequences of Infant Infection. Current Immunology Reviews, 2019, 15, 131-138.	1.2	0
1455	HIV and SIV in Body Fluids: From Breast Milk to the Genitourinary Tract. Current Immunology Reviews, 2019, 15, 139-152.	1.2	6
1459	Immunobiological Correlates of SIV Vaccine Vectors and Macaque Tropism. Vaccine Research, 2019, 6, 23-36.	0.3	0
1463	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. Retrovirology, 2021, 18, 35.	0.9	7
1464	HIV prevention in a time of COVID-19: A report from the HIVR4P // Virtual conference 2021. AIDS Research and Human Retroviruses, 2021, , .	0.5	1
1465	Striking a balance in an antibody network: A roadmap for HIV-1 vaccines. Journal of Clinical Investigation, 2019, 129, 4580-4582.	3.9	0
1466	Prevention of HIV Infection. , 2020, , 1-29.		0
1467	The Emerging of CRF01_AE: A Clinical Story and Future HIV/AIDS Situation in Thailand. Current HIV Research, 2020, 18, 74-84.	0.2	1
1468	Internalization of HIV-1 by Phagocytes Is Increased When Virions Are Opsonized with Multimeric Antibody in the Presence of Complement. Journal of Virology, 2022, 96, JVI0168921.	1.5	0

#	ARTICLE	IF	CITATIONS
1469	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. <i>Journal of Virology</i> , 2021, , JVI0164321.	1.5	7
1470	Intranasal vaccination with a Chimeric Chlamydial Antigen BD584 confers protection against <i>Chlamydia trachomatis</i> genital tract infection. <i>Journal of Vaccines and Immunology</i> , 2020, , 010-017.	0.3	1
1471	Distributions associated with simultaneous multiple hypothesis testing. <i>Journal of Statistical Distributions and Applications</i> , 2020, 7, .	1.2	1
1476	New prospects for a preventive HIV-1 vaccine. <i>Journal of Virus Eradication</i> , 2015, 1, 78-88.	0.3	1
1477	HIV-1 prophylactic vaccines: state of the art. <i>Journal of Virus Eradication</i> , 2016, 2, 5-11.	0.3	10
1480	Neutralization and beyond: Antibodies and HIV-1 acquisition. <i>Current Topics in Virology</i> , 2018, 15, 73-86.	0.0	1
1481	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
1482	Current approaches to HIV vaccine development: a narrative review. <i>Journal of the International AIDS Society</i> , 2021, 24, e25793.	1.2	35
1483	Engaging innate immunity in HIV-1 cure strategies. <i>Nature Reviews Immunology</i> , 2022, 22, 499-512.	10.6	39
1484	Strategies for induction of HIV envelope-reactive broadly neutralizing antibodies. <i>Journal of the International AIDS Society</i> , 2021, 24, e25831.	1.2	19
1485	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021, 17, e1010016.	2.1	1
1486	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. <i>PLoS Pathogens</i> , 2021, 17, e1010046.	2.1	6
1487	Identification of HIV-Reservoir Cells With Reduced Susceptibility to Antibody-Dependent Immune Response. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1488	Una vacuna preventiva frente al VIH. Situación actual y perspectivas. <i>Revista De Investigación Y Educación En Ciencias De La Salud (RIECS)</i> , 2020, 5, 81-90.	0.0	0
1489	Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study. <i>ELife</i> , 2022, 11, .	2.8	4
1490	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. <i>Frontiers in Immunology</i> , 2021, 12, 787603.	2.2	1
1491	A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates. <i>Vaccine</i> , 2022, 40, 239-246.	1.7	2
1492	Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates. <i>Vaccines</i> , 2022, 10, 187.	2.1	2



#	ARTICLE	IF	CITATIONS
1493	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. <i>PLoS Pathogens</i> , 2022, 18, e1010183.	2.1	8
1494	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. <i>Current HIV/AIDS Reports</i> , 2022, 19, 86.	1.1	6
1495	Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV. <i>Npj Vaccines</i> , 2022, 7, 18.	2.9	2
1496	Monocyte Gene and Molecular Expression Profiles Suggest Distinct Effector and Regulatory Functions in Beninese HIV Highly Exposed Seronegative Female Commercial Sex Workers. <i>Viruses</i> , 2022, 14, 361.	1.5	3
1497	A multiclade envâ€gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <i>Nature Medicine</i> , 2021, 27, 2234-2245.	15.2	80
1498	E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. <i>Vaccines</i> , 2022, 10, 295.	2.1	2
1500	Estimation of conditional cumulative incidence functions under generalized semiparametric regression models with missing covariates, with application to analysis of biomarker correlates in vaccine trials. <i>Canadian Journal of Statistics</i> , 0, , .	0.6	0
1501	Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection. <i>MSphere</i> , 2022, 7, e0083921.	1.3	2
1502	Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. <i>Toxins</i> , 2022, 14, 138.	1.5	6
1503	Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges. <i>Frontiers in Immunology</i> , 2022, 13, 788619.	2.2	4
1504	A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcÎ³R Complex Formation After Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 820148.	2.2	1
1505	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. <i>Nature Communications</i> , 2022, 13, 903.	5.8	7
1507	Testing a global null hypothesis using ensemble machine learning methods. <i>Statistics in Medicine</i> , 2022, , , .	0.8	0
1508	Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies. <i>Cell Reports</i> , 2022, 38, 110436.	2.9	6
1510	Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child transmission. <i>JCI Insight</i> , 2022, 7, .	2.3	5
1511	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. <i>Journal of Virology</i> , 2022, , e0003422.	1.5	7
1512	Omicronâ€™s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. <i>IScience</i> , 2022, 25, 104076.	1.9	25
1513	FcÎ³R Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 788203.	2.2	2

#	ARTICLE	IF	CITATIONS
1514	Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection. <i>Cells</i> , 2022, 11, 77.	1.8	1
1515	Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques. <i>PLoS ONE</i> , 2021, 16, e0256885.	1.1	1
1516	Impact of Coinfection With SARS-CoV-2 and Influenza on Disease Severity: A Systematic Review and Meta-Analysis. <i>Frontiers in Public Health</i> , 2021, 9, 773130.	1.3	36
1517	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	2.9	2
1518	Novel Compound Inhibitors of HIV-1NL4-3 Vpu. <i>Viruses</i> , 2022, 14, 817.	1.5	2
1570	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. <i>Vaccines</i> , 2022, 10, 717.	2.1	15
1571	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	15.2	44
1572	Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants in Children With Coronavirus Disease 2019, Multisystem Inflammatory Syndrome in Children, and After Two Doses of BNT162b2 Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1237-1242.	1.9	12
1573	Natural Killer Cells in Antibody Independent and Antibody Dependent HIV Control. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
1574	NK Cells in Protection from HIV Infection. <i>Viruses</i> , 2022, 14, 1143.	1.5	3
1575	Leveraging South African HIV research to define SARS-CoV-2 immunity triggered by sequential variants of concern. <i>Immunological Reviews</i> , 2022, 310, 61-75.	2.8	6
1576	Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response. <i>ELife</i> , 0, 11, .	2.8	10
1579	Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development. <i>Annual Review of Virology</i> , 2022, 9, 491-520.	3.0	13
1580	Severe acute respiratory syndrome coronavirus 2 variants—Possibility of universal vaccine design: A review. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3533-3544.	1.9	3
1581	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. <i>PLoS Pathogens</i> , 2022, 18, e1010574.	2.1	6
1582	Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2. <i>Vaccine</i> , 2022, 40, 4174-4181.	1.7	1
1583	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. <i>Journal of Immunology</i> , 2022, 208, 2663-2674.	0.4	8
1584	Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	34

#	ARTICLE	IF	CITATIONS
1585	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€“3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	1.9	11
1586	HLA-B*46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. <i>Cell Host and Microbe</i> , 2022, 30, 1173-1185.e8.	5.1	5
1587	The use of viral vectors in vaccine development. <i>Npj Vaccines</i> , 2022, 7, .	2.9	73
1589	A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques. <i>Science Immunology</i> , 2022, 7, .	5.6	7
1590	Highly mutated monoclonal antibody 3F2 targets a conformational and strain-restricted epitope in human immunodeficiency virus gp41 with significant antibody-dependent cell cytotoxicity. <i>Archives of Virology</i> , 2022, 167, 2193-2201.	0.9	1
1591	The HIV Reservoir and Cure and Remission Strategies. , 2021, , 199-217.		0
1592	Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1. <i>Npj Vaccines</i> , 2022, 7, .	2.9	1
1594	Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1595	Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. <i>Nature Reviews Immunology</i> , 2023, 23, 142-158.	10.6	91
1596	Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
1597	Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2022, 226, 1667-1677.	1.9	4
1598	Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. <i>Nature Medicine</i> , 2022, 28, 1924-1932.	15.2	42
1599	Recent advances in the vaccine development for the prophylaxis of SARS Covid-19. <i>International Immunopharmacology</i> , 2022, 111, 109175.	1.7	5
1600	FCGR3A gene duplication, FcÎ³RIIb-232TT and FcÎ³RIIb-HNA1a associate with an increased risk of vertical acquisition of HIV-1. <i>PLoS ONE</i> , 2022, 17, e0273933.	1.1	1
1601	Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. <i>EBioMedicine</i> , 2022, 84, 104271.	2.7	1
1602	Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1603	Leveraging lessons learned from the COVID-19 pandemic for HIV. <i>Communications Medicine</i> , 2022, 2, .	1.9	2
1604	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8

#	ARTICLE	IF	CITATIONS
1605	Self-assembling peptide nanofiber HIV vaccine elicits robust vaccine-induced antibody functions and modulates Fc glycosylation. <i>Science Advances</i> , 2022, 8, .	4.7	6
1607	Human NK cells confer protection against HIV-1 infection in humanized mice. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	6
1608	Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial. <i>PLoS ONE</i> , 2022, 17, e0275927.	1.1	0
1609	Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study. <i>Journal of Infectious Diseases</i> , 2023, 227, 939-950.	1.9	4
1610	HIV-1 Vpu restricts Fc-mediated effector functions in vivo. <i>Cell Reports</i> , 2022, 41, 111624.	2.9	8
1611	CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults. <i>Immunobiology</i> , 2023, 228, 152304.	0.8	2
1612	Improved inference for vaccine-induced immune responses via shape-constrained methods. <i>Electronic Journal of Statistics</i> , 2022, 16, .	0.4	0
1613	Probiotic therapy during vaccination alters antibody response to SHIV infection but not to commensals. <i>AIDS Research and Human Retroviruses</i> , 0, , .	0.5	0
1615	Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. <i>Science Immunology</i> , 2023, 8, .	5.6	89
1616	Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B Cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques. <i>Viruses</i> , 2022, 14, 2819.	1.5	1
1617	Fc receptor engagement of HIV-1 Env-specific antibodies in mothers and infants predicts reduced vertical transmission. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1618	Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers. <i>Journal of Virology</i> , 2022, 96, .	1.5	4
1620	Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1621	Natural killer cells for antiviral therapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	3
1622	Mapping the interplay between NK cells and HIV: therapeutic implications. <i>Journal of Leukocyte Biology</i> , 2023, 113, 109-138.	1.5	1
1623	Self-assembled protein nanoparticles for multifunctional theranostic uses. , 2023, , 345-366.		0
1625	Mycobacterium tuberculosis disease associates with higher HIV-1-specific antibody responses. <i>IScience</i> , 2023, 26, 106631.	1.9	1
1626	HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC. <i>Nature Communications</i> , 2023, 14, .	5.8	8

#	ARTICLE	IF	CITATIONS
1627	Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies. <i>Journal of Virology</i> , 2023, 97, .	1.5	4
1628	HIV/AIDS Global Epidemic. , 2023, , 221-250.		1
1629	Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines. <i>Vaccines</i> , 2023, 11, 376.	2.1	0
1630	Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans. <i>AIDS Research and Human Retroviruses</i> , 2023, 39, 350-366.	0.5	2
1631	Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	4
1632	A tool for evaluating heterogeneity in avidity of polyclonal antibodies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1633	Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251. <i>Nature Communications</i> , 2023, 14, .	5.8	0
1634	Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial. <i>Vaccine</i> , 2023, 41, 2696-2706.	1.7	2
1635	Identification of peptide epitopes of the gp120 protein of HIV-1 capable of inducing cellular and humoral immunity. <i>RSC Advances</i> , 2023, 13, 9078-9090.	1.7	0
1636	Effect of Passive Administration of Monoclonal Antibodies Recognizing Simian Immunodeficiency Virus (SIV) V2 in CH59-Like Coil/Helical or $\beta$ -Sheet Conformations on Time of SIV <sub>mac251</sub> Acquisition. <i>Journal of Virology</i> , 0, , .	1.5	2
1637	Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques. <i>Nature Microbiology</i> , 2023, 8, 905-918.	5.9	3
1638	Severe COVID-19: Drugs and Clinical Trials. <i>Journal of Clinical Medicine</i> , 2023, 12, 2893.	1.0	0
1639	Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIVmac251 acquisition in macaques. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1649	Prevention, treatment and cure of HIV infection. <i>Nature Reviews Microbiology</i> , 2023, 21, 657-670.	13.6	21
1653	Human Immunodeficiency Virus Vaccines. , 2023, , 458-483.e15.		0
1654	Correlates of Protection. , 2023, , 45-51.e5.		1
1655	HIV/AIDS Prevention. , 2024, , 139-151.		0
1657	Challenges and opportunities: structural racism and its impact on COVID-19. , 2023, , 165-182.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------